<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FENTANYL CITRATE- fentanyl citrateÂ lozengeÂ </strong><br>Lake Erie Medical DBA Quality Care Products LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Oral Transmucosal Fentanyl Citrate (OTFC) safely and effectively.  See full prescribing information for OTFC.<br>Oral Transmucosal Fentanyl Citrate (OTFC), CII<br>Initial U.S. Approval: 1968</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: RISK OF <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>, MEDICATION ERRORS, ABUSE POTENTIAL</h1>
<h1 class="Warning">See full prescribing information for complete boxed warning.</h1>
<dl>
<dt>â€¢</dt>
<dd>Due to the risk of fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, OTFC is contraindicated in opioid non-tolerant patients (<a href="#i4i_indications_id_c321338a-20c5-44ec-aa29-f6270c647bcc">1</a>) and in management of acute or <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span>, including <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>/<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>. (<a href="#i4i_contraindications_id_73c75da0-5a3e-48db-9829-84bcdc4700c4">4</a>) </dd>
<dt>â€¢</dt>
<dd>Keep out of reach of children. (<a href="#i4i_section_id_6b0f9ad8-fdbe-4f32-92c1-a012f09eb7be">5.3</a>)</dd>
<dt>â€¢</dt>
<dd>Use with CYP 3A4 inhibitors may cause fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. (<a href="#i4i_interactions_id_37e8901a-4567-4139-802b-518bcbd7bba7">7</a>) </dd>
<dt>â€¢</dt>
<dd>When prescribing, do not convert patients on a mcg per mcg basis from any other oral transmucosal fentanyl product to OTFC. (<a href="#i4i_section_id_d6bf81ac-7afe-4502-86b4-9175b6a4daa1">2.1</a>, <a href="#inv-c65775f0-7877-4d35-a894-db3f0c991184">5.1</a>)</dd>
<dt>â€¢</dt>
<dd>When dispensing, do not substitute with any other fentanyl products. (<a href="#inv-c65775f0-7877-4d35-a894-db3f0c991184">5.1</a>)</dd>
<dt>â€¢</dt>
<dd>Contains fentanyl, a Schedule II controlled substance with abuse liability similar to other opioid analgesics. (<a href="#i4i_controlled_substance_id_339d7edc-255c-48e0-b2aa-a166a17c9919">9.1</a>) </dd>
<dt>â€¢</dt>
<dd>Oral Transmucosal Fentanyl Citrate (OTFC) is available only through a restricted program called the TIRF REMS Access program. Outpatients, healthcare professionals who prescribe to outpatients, pharmacies and distributors are required to enroll in the program. (<a href="#inv-80726b26-6050-4911-b26b-bdc2f5fd4dc9">5.10</a>)</dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Indications and Usage ( <a href="#i4i_indications_id_c321338a-20c5-44ec-aa29-f6270c647bcc">1</a>)   12/2011 </p>
<p class="Highlighta">Warnings and Precautions â€“ TIRF REMS Access Program ( <a href="#inv-80726b26-6050-4911-b26b-bdc2f5fd4dc9">5.10</a>)   12/2011 </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: RISK OF <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>, MEDICATION ERRORS, ABUSE POTENTIAL</h1>
<h1 class="Warning">See full prescribing information for complete boxed warning.</h1>
<dl>
<dt>â€¢</dt>
<dd>Due to the risk of fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, OTFC is contraindicated in opioid non-tolerant patients (<a href="#i4i_indications_id_c321338a-20c5-44ec-aa29-f6270c647bcc">1</a>) and in management of acute or <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span>, including <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>/<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>. (<a href="#i4i_contraindications_id_73c75da0-5a3e-48db-9829-84bcdc4700c4">4</a>) </dd>
<dt>â€¢</dt>
<dd>Keep out of reach of children. (<a href="#i4i_section_id_6b0f9ad8-fdbe-4f32-92c1-a012f09eb7be">5.3</a>)</dd>
<dt>â€¢</dt>
<dd>Use with CYP 3A4 inhibitors may cause fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. (<a href="#i4i_interactions_id_37e8901a-4567-4139-802b-518bcbd7bba7">7</a>) </dd>
<dt>â€¢</dt>
<dd>When prescribing, do not convert patients on a mcg per mcg basis from any other oral transmucosal fentanyl product to OTFC. (<a href="#i4i_section_id_d6bf81ac-7afe-4502-86b4-9175b6a4daa1">2.1</a>, <a href="#inv-c65775f0-7877-4d35-a894-db3f0c991184">5.1</a>)</dd>
<dt>â€¢</dt>
<dd>When dispensing, do not substitute with any other fentanyl products. (<a href="#inv-c65775f0-7877-4d35-a894-db3f0c991184">5.1</a>)</dd>
<dt>â€¢</dt>
<dd>Contains fentanyl, a Schedule II controlled substance with abuse liability similar to other opioid analgesics. (<a href="#i4i_controlled_substance_id_339d7edc-255c-48e0-b2aa-a166a17c9919">9.1</a>) </dd>
<dt>â€¢</dt>
<dd>Oral Transmucosal Fentanyl Citrate (OTFC) is available only through a restricted program called the TIRF REMS Access program. Outpatients, healthcare professionals who prescribe to outpatients, pharmacies and distributors are required to enroll in the program. (<a href="#inv-80726b26-6050-4911-b26b-bdc2f5fd4dc9">5.10</a>)</dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Oral Transmucosal Fentanyl Citrate (OTFC) is an opioid agonist indicated for the management of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in cancer patients 16 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> ( <a href="#i4i_indications_id_c321338a-20c5-44ec-aa29-f6270c647bcc">1</a>).  </p>
<p class="Highlighta">Limitations of Use: </p>
<p class="Highlighta">OTFC may be dispensed only to patients enrolled in the TIRF REMS Access program. ( <a href="#i4i_indications_id_c321338a-20c5-44ec-aa29-f6270c647bcc">1</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Patients must require and use around-the-clock opioids when taking OTFC. (<a href="#i4i_indications_id_c321338a-20c5-44ec-aa29-f6270c647bcc">1</a>)</dd>
<dt>â€¢</dt>
<dd>Initial dose of Oral Transmucosal Fentanyl Citrate (OTFC): 200 mcg.Â  Prescribe an initial supply of six 200 mcg OTFC units. (<a href="#i4i_section_id_d6bf81ac-7afe-4502-86b4-9175b6a4daa1">2.1</a>)</dd>
<dt>â€¢</dt>
<dd>Individually titrate to a tolerable dose that provides adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> using single OTFC dosage unit per breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> episode.  (<a href="#i4i_section_id_d6bf81ac-7afe-4502-86b4-9175b6a4daa1">2.1</a>)</dd>
<dt>â€¢</dt>
<dd>No more than two doses can be taken per breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> episode. (<a href="#i4i_section_id_71e511e7-9665-4959-bbaf-0a99ae9605e7">2.2</a>)</dd>
<dt>â€¢</dt>
<dd>Wait at least 4 hours before treating another episode of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with OTFC. (<a href="#i4i_section_id_c6d3931d-83ea-4a15-9837-dab904ac924e">2.3</a>)</dd>
<dt>â€¢</dt>
<dd>Limit consumption to four or fewer units per day once successful dose is found. (<a href="#i4i_section_id_c6d3931d-83ea-4a15-9837-dab904ac924e">2.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Solid oral transmucosal lozenge in 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1200 mcg and 1600 mcg. (<a href="#i4i_dosage_form_strength_id_43bb858f-d298-4bc7-9ac7-570142ad2d8e">3</a>) </dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Opioid non-tolerant patients. (<a href="#i4i_contraindications_id_73c75da0-5a3e-48db-9829-84bcdc4700c4">4</a>)</dd>
<dt>â€¢</dt>
<dd>Management of acute or <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span> including <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>/<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> and dental <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. (<a href="#i4i_contraindications_id_73c75da0-5a3e-48db-9829-84bcdc4700c4">4</a>)</dd>
<dt>â€¢</dt>
<dd>Intolerance or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to fentanyl or components of OTFC. (<a href="#i4i_contraindications_id_73c75da0-5a3e-48db-9829-84bcdc4700c4">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Clinically significant respiratory and <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> can occur.  Monitor patients accordingly. (<a href="#_Ref">5.2</a>)</dd>
<dt>â€¢</dt>
<dd>Full and partially consumed Oral Transmucosal Fentanyl Citrate (OTFC) units contain medicine that can be fatal to a child.  Ensure proper storage and disposal. Interim safe storage container available (â€œOTFC Child Safety Kitâ€?). (<a href="#i4i_section_id_6b0f9ad8-fdbe-4f32-92c1-a012f09eb7be">5.3</a>)</dd>
<dt>â€¢</dt>
<dd>Use with other CNS depressants and potent cytochrome P450 3A4 inhibitors may increase depressant effects including <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and profound sedation. Consider dosage adjustments if warranted. (<a href="#i4i_section_id_9818bbf6-fc17-4204-a05f-c41402041285">5.4</a>) </dd>
<dt>â€¢</dt>
<dd>Titrate OTFC cautiously in patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> or preexisting medical conditions predisposing them to <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and in patients susceptible to intracranial effects of CO<span class="Sub">2</span> retention. (<a href="#i4i_section_id_4f3eb6a5-f2dd-4550-b4d8-e1c2a941f449">5.6</a>, <a href="#i4i_section_id_d1256612-965e-41fe-88f9-e20d255da009">5.7</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Â Most common (frequency â‰¥5%): <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>. ( <a href="#i4i_section_id_57951dbc-f9b9-4f8f-b2d1-cce660703e3e">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Par Pharmaceutical at 1-800-828-9393 option 2 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>See Boxed Warning and <span class="Bold">WARNINGS AND PRECAUTIONS</span> (<a href="#i4i_section_id_9818bbf6-fc17-4204-a05f-c41402041285">5.4</a>, <a href="#i4i_interactions_id_37e8901a-4567-4139-802b-518bcbd7bba7">7</a>)  </dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Administer Oral Transmucosal Fentanyl Citrate (OTFC) with caution to patients with liver or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">kidney dysfunction</span>. (<a href="#i4i_section_id_5e93a67f-2d49-4030-b2fd-3277ad1f99aa">8.6</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 8/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">BOXED WARNING</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Initial Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dose Titration</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Maintenance DosingÂ  </a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Administration of OTFC</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Discontinuation of OTFC</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Important Information Regarding Prescribing and Dispensing </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Patient/Caregiver Instructions</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Additive CNS Depressant Effects</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Effects on Ability to Drive and Use Machines</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Chronic Pulmonary Disease</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Head Injuries and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Cardiac Disease</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 MAO Inhibitors</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access Program</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 Patients with Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7 Gender</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse and Addiction</a></h2>
<h2><a href="#section-9.3" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Clinical Presentation</a></h2>
<h2><a href="#section-10.2" class="toc">10.2 Immediate Management</a></h2>
<h2><a href="#section-10.3" class="toc">10.3 Treatment of Overdosage (Accidental Ingestion) in the Opioid NON-Tolerant Person</a></h2>
<h2><a href="#section-10.4" class="toc">10.4 Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> in Opioid-Tolerant Patients</a></h2>
<h2><a href="#section-10.5" class="toc">10.5 General Considerations for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 Storage and Handling</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Disposal of OTFC</a></h2>
<h2><a href="#section-15.3" class="toc">16.3 How Supplied</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Patient/Caregiver Instructions</a></h2>
<h2><a href="#section-16.2" class="toc">17.2 Dental Care</a></h2>
<h2><a href="#section-16.3" class="toc">17.3 Diabetic Patients</a></h2>
<h2><a href="#section-16.4" class="toc">17.4 OTFC Child Safety Kit</a></h2>
<h2><a href="#section-16.5" class="toc">17.5 Disposal of Used OTFC Units</a></h2>
<h2><a href="#section-16.6" class="toc">17.6 Disposal of Unopened OTFC Units When No Longer Needed</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="inv-bc9b6baa-c122-4e6d-b62e-d1f271108ae8"></a><a name="section-1"></a><p></p>
<h1>BOXED WARNING</h1>
<p class="First"><span class="Bold">WARNING: RISK OF <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>, MEDICATION ERRORS, ABUSE POTENTIAL</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span></span></p>
<p><span class="Bold">Fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> has occurred in patients treated with OTFC, including following use in opioid non-tolerant patients and improper dosing. The substitution of OTFC for any other fentanyl product may result in fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</span></p>
<p><span class="Bold">Due to the risk of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, OTFC is contraindicated in the management of acute or <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span> including <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>/<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> and in opioid non-tolerant patients. [ see Contraindications (<a href="#i4i_contraindications_id_73c75da0-5a3e-48db-9829-84bcdc4700c4">4</a>)].</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> has been reported in children who have accidentally ingested Oral Transmucosal Fentanyl Citrate (OTFC). OTFC must be kept out of reach of children. [ see Patient Counseling Information (<a href="#i4i_section_id_f7eaa487-bc94-4d15-ba28-f91fcbe99613">17.3</a>) and How Supplied/Storage and Handling(<a href="#i4i_section_id_c9569ac2-f8e5-492d-b4ee-67300f5e78a9">16.1</a>)]</span></p>
<p>The concomitant use of OTFC with CYP3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> [see <span class="Bold">Drug Interactions</span> (<a href="#i4i_interactions_id_37e8901a-4567-4139-802b-518bcbd7bba7">7</a>)].</p>
<p><span class="Bold">MEDICATION ERRORS</span></p>
<p><span class="Bold">Substantial differences exist in the pharmacokinetic profile of OTFC compared to other fentanyl products that result in clinically important differences in the extent of absorption of fentanyl that could result in fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</span></p>
<p><span class="Bold">When prescribing, do not convert patients on a mcg per mcg basis from any other fentanyl products to Oral Transmucosal Fentanyl Citrate (OTFC). [ see Dosage and Administration (<a href="#i4i_section_id_d6bf81ac-7afe-4502-86b4-9175b6a4daa1">2.1</a>)]</span></p>
<p><span class="Bold">When dispensing, do not substitute an OTFC prescription for other fentanyl products</span>. </p>
<p><span class="Bold">ABUSE POTENTIAL</span></p>
<p><span class="Bold">Oral Transmucosal Fentanyl Citrate (OTFC) contains fentanyl, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. OTFC can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing OTFC in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion</span>. </p>
<p>Because of the risk for misuse, abuse, addiction, and <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, OTFC is available only through a restricted program, required by the Food and Drug Administration, called the Risk Evaluation and Mitigation Strategy (REMS). Under the Transmucosal Immediate Release Fentanyl (TIRF) REMS Access program, outpatients, healthcare professionals who prescribe to outpatients, pharmacies and distributors must enroll in the program. [See <span class="Bold">Warnings and Precautions</span> (<a href="#inv-80726b26-6050-4911-b26b-bdc2f5fd4dc9">5.10</a>)] Further information is available at www.TIRFREMSAccess.com or by calling 1-866-822-1483. </p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_c321338a-20c5-44ec-aa29-f6270c647bcc"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Oral Transmucosal Fentanyl Citrate (OTFC) is indicated for the management of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in cancer patients 16 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Patients considered opioid tolerant are those who are taking around-the-clock medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oral oxycodone daily, at least 8 mg of oral hydromorphone daily, at least 25 mg oral oxymorphone daily, or an equianalgesic dose of another opioid daily for a week or longer. Patients must remain on around-the-clock opioids when taking OTFC.</p>
<p>This product <span class="Bold"><span class="Underline">must not</span></span> be used in opioid non-tolerant patients because life-threatening <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> could occur at any dose in patients not on a chronic regimen of opioids. For this reason, OTFC is contraindicated in the management of acute or <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span>.</p>
<p>OTFC is intended to be used only in the care of cancer patients and only by oncologists and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> specialists who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p>Limitations of Use:</p>
<p>As a part of the TIRF REMS Access Program, OTFC may be dispensed only to outpatients enrolled in the program [see <span class="Bold">Warnings and Precautions</span> (<a href="#inv-80726b26-6050-4911-b26b-bdc2f5fd4dc9">5.10</a>)].  For inpatient administration of OTFC (e.g., hospitals, hospices, and long-term care facilities that prescribe for inpatient use) patient and prescriber enrollment is not required.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_6ff90ac8-3420-46cd-b19f-1c7a93ebbe9b"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Healthcare professionals who prescribe OTFC on an outpatient basis must enroll in the TIRF REMS Access program and comply with the requirements of the REMS to ensure safe use of OTFC [see <span class="Bold">WARNINGS AND PRECAUTIONS</span> (<a href="#inv-80726b26-6050-4911-b26b-bdc2f5fd4dc9">5.10</a>)].</p>
<p>As with all opioids, the safety of patients using such products is dependent on healthcare professionals prescribing them in strict conformity with their approved labeling with respect to patient selection, dosing, and proper conditions for use.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d6bf81ac-7afe-4502-86b4-9175b6a4daa1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Initial Dose</h2>
<p class="First">Individually titrate Oral Transmucosal Fentanyl Citrate (OTFC) to a dose that provides adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> and minimizes side effects. The initial dose of OTFC to treat episodes of breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> is <span class="Bold">always </span>200 mcg<span class="Italics">. </span>The OTFC unit should be consumed over 15 minutes. Patients should be prescribed an initial titration supply of six 200 mcg OTFC units, thus limiting the number of units in the home during titration. Patients should use up all units before increasing to a higher dose to prevent <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and possible <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_71e511e7-9665-4959-bbaf-0a99ae9605e7"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dose Titration</h2>
<p class="First">From this initial dose, closely follow patients and change the dosage level until the patient reaches a dose that provides adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> using a single OTFC dosage unit per breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> episode. If signs of excessive opioid effects appear before the unit is consumed, the dosage unit should be removed from the patientâ€™s mouth immediately, disposed of properly, and subsequent doses should be decreased. Patients should record their use of OTFC over several episodes of breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and review their experience with their physicians to determine if a dosage adjustment is warranted.</p>
<p>In cases where the breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> episode is not relieved 15 minutes after completion of the OTFC unit (30 minutes after the start of the unit), patients may take <span class="Bold">ONLY ONE </span>additional dose of the same strength for that episode. Thus, patients should take a maximum of two doses of OTFC for any breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> episode.</p>
<p>Patients must wait <span class="Bold">at least 4 hours </span>before treating another episode of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with OTFC. To reduce the risk of overdosing during titration, patients should have only one strength of OTFC available at any one time.</p>
<div class="Figure"><img alt="this is a chart" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-01.jpg"></div>
<div class="Figure"><img alt="this is the chart" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-02.jpg"></div>
<p>* Available dosage strengths include: 200, 400, 600, 800, 1200, and 1600 mcg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c6d3931d-83ea-4a15-9837-dab904ac924e"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Maintenance DosingÂ  </h2>
<p class="First">Once titrated to an effective dose, patients should generally use <span class="Bold">ONLY ONE </span>Oral Transmucosal Fentanyl Citrate (OTFC) unit of the appropriate strength per breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> episode. </p>
<p>On those occasions when the breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> episode is not relieved 15 minutes after completion of the OTFC unit, patient may take <span class="Bold">ONLY ONE </span>additional dose using the same strength for that episode. </p>
<p>Patients MUST wait <span class="Bold">at least 4 hours </span>before treating another episode of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with OTFC. Once a successful dose has been found (i.e., an average episode is treated with a single unit), patients should limit consumption to four or fewer units per day. </p>
<p>Dosage adjustment of OTFC may be required in some patients in order to continue to provide adequate relief of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p>Generally, the OTFC dose should be increased only when a single administration of the current dose fails to adequately treat the breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> episode for several consecutive episodes.</p>
<p>If the patient experiences greater than four breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> episodes per day, the dose of the maintenance (around-the-clock) opioid used for persistent <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> should be re-evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2d10231c-a1b3-4954-a014-6086d4401157"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Administration of OTFC</h2>
<p class="First">Open the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package with scissors immediately prior to product use. The patient should place the Oral Transmucosal Fentanyl Citrate (OTFC) unit in his or her mouth between the cheek and lower gum, occasionally moving the drug matrix from one side to the other using the handle. The OTFC unit should be sucked, not chewed. A unit dose of OTFC, if chewed and swallowed, might result in lower peak concentrations and lower bioavailability than when consumed as directed [ <span class="Italics">see <span class="Bold">Clinical Pharmacology</span> (<a href="#i4i_pharmacokinetics_id_ebfe50d2-6256-44d9-85dc-c1608b418ac8">12.3</a>)</span>].</p>
<p>The OTFC unit should be consumed over a 15-minute period. Longer or shorter consumption times may produce less efficacy than reported in OTFC clinical trials. If signs of excessive opioid effects appear before the unit is consumed, remove the drug matrix from the patientâ€™s mouth immediately and decrease future doses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_acadc260-fcca-4646-bc32-bc6146a4cb79"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Discontinuation of OTFC</h2>
<p class="First">For patients requiring discontinuation of opioids, a gradual downward titration is recommended because it is not known at what dose level the opioid may be discontinued without producing the signs and symptoms of abrupt withdrawal.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_43bb858f-d298-4bc7-9ac7-570142ad2d8e"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Each dosage unit has white to off-white color and is a solid drug matrix on a handle. Each strength is marked on the individual solid drug matrix and the handle tag. Oral Transmucosal Fentanyl Citrate (OTFC) is available in 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1200 mcg and 1600 mcg strengths [see <span class="Bold">How Supplied/Storage And Handling</span> (<a href="#i4i_section_id_50e11a2a-022d-4627-bd40-08190ed75945">16.3</a>)].</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_73c75da0-5a3e-48db-9829-84bcdc4700c4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">OTFC is contraindicated in opioid non-tolerant patients. OTFC is contraindicated in the management of acute or <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span> including <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>/<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> and dental <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Life-threatening <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> could occur at any dose in opioid non-tolerant patients.</p>
<p>Patients considered opioid tolerant are those who are taking around-the-clock medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oral oxycodone daily, at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid daily for a week or longer.</p>
<p>OTFC is contraindicated in patients with known intolerance or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components or the drug fentanyl. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> have been reported in association with the use of OTFC.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_75d1eb49-4d5e-4962-aa01-5b8d15f49f10"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First"><span class="Bold"><span class="Italics">See Boxed Warning - WARNING:  RISK OF <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>, MEDICATION ERRORS, ABUSE POTENTIAL</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-c65775f0-7877-4d35-a894-db3f0c991184"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> is the chief hazard of opioid agonists, including fentanyl, the active ingredient in ACTIQ. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> is more likely to occur in patients with underlying <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorders</span> and elderly or debilitated patients, usually following large initial doses in opioid non-tolerant patients, or when opioids are given in conjunction with other drugs that depress respiration.</p>
<p><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> from opioids is manifested by a reduced urge to breathe and a decreased rate of respiration, often associated with the â€œsighingâ€? pattern of breathing (deep breaths separated by abnormally long pauses). <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">Carbon dioxide</span> retention from opioid-induced <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> can exacerbate the sedating effects of opioids. This makes <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> involving drugs with sedative properties and opioids especially dangerous.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b3a6c75f-d023-4300-aa81-f10ab5c83776"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Important Information Regarding Prescribing and Dispensing </h2>
<p class="First"><span class="Bold">When prescribing, DO NOT convert a patient to OTFC from any other fentanyl product on a mcg per mcg basis </span>as OTFC and other fentanyl products are not equivalent on a microgram per microgram basis. </p>
<p>OTFC is NOT a generic version of fentanyl buccal tablets (Fentora <span class="Sup">Â®</span>). <span class="Bold">When dispensing, DO NOT substitute an OTFC prescription for fentanyl buccal tablets (Fentora<span class="Sup">Â®</span>) prescription under any circumstances. Fentanyl buccal tablets (Fentora<span class="Sup">Â®</span>) and OTFC are not equivalent. </span>Substantial differences exist in the pharmacokinetic profile of OTFC compared to other fentanyl products including fentanyl buccal tablets (Fentora<span class="Sup">Â®</span>) that result in clinically important differences in the rate and extent of absorption of fentanyl. <span class="Bold">As a result of these differences, the substitution of OTFC for any other fentanyl product may result in a fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. </span></p>
<p><span class="Bold">There are no safe conversion directions available for patients on any other fentanyl products. (Note: This includes oral, transdermal, or parenteral formulations of fentanyl.) </span>Therefore, for opioid tolerant patients, the initial dose of OTFC should <span class="Bold">always </span>be 200 mcg. Each patient should be individually titrated to provide adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> while minimizing side effects [see <span class="Bold">Dosage And Administration</span> (<a href="#i4i_section_id_71e511e7-9665-4959-bbaf-0a99ae9605e7">2.2</a>)]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6b0f9ad8-fdbe-4f32-92c1-a012f09eb7be"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Patient/Caregiver Instructions</h2>
<p class="First"><span class="Bold">Patients and their caregivers must be instructed that Oral Transmucosal Fentanyl Citrate (OTFC) contains a medicine in an amount which can be fatal to a child. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> has been reported in children who have accidentally ingested OTFC.</span> Patients and their caregivers must be instructed to keep both used and unused dosage units out of the reach of children. While all units should be disposed of immediately after use, partially consumed units represent a special risk to children. In the event that a unit is not completely consumed it must be properly disposed as soon as possible [s<span class="Italics">ee <span class="Bold">How Supplied/Storage And Handling</span>, (<a href="#i4i_section_id_c9569ac2-f8e5-492d-b4ee-67300f5e78a9">16.1</a>, <a href="#i4i_section_id_4fc9421d-5313-423c-b4e4-b0a17d756de0">16.2</a>)</span>, <span class="Italics">and <span class="Bold">Patient Counseling Information</span> (<a href="#i4i_section_id_f7eaa487-bc94-4d15-ba28-f91fcbe99613">17.3</a>) and <span class="Bold">Medication Guide</span>]</span>.</p>
<p>Physicians and dispensing pharmacists must specifically question patients or caregivers about the presence of children in the home (on a full time or visiting basis) and counsel them regarding the dangers to children from inadvertent exposure.</p>
<p>OTFC could be fatal to individuals for whom it is not prescribed and for those who are not opioid-tolerant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9818bbf6-fc17-4204-a05f-c41402041285"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Additive CNS Depressant Effects</h2>
<p class="First">The concomitant use of OTFC with other CNS depressants, including other opioids, sedatives or hypnotics, general anesthetics, phenothiazines, tranquilizers, skeletal muscle relaxants, sedating antihistamines, and alcoholic beverages may produce increased depressant effects (e.g., <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and profound sedation). Concomitant use with potent inhibitors of cytochrome P450 3A4 isoform (e.g., erythromycin, ketoconazole, and certain protease inhibitors) may increase fentanyl levels, resulting in increased depressant effects [ <span class="Italics">see Drug Interactions (<a href="#i4i_interactions_id_37e8901a-4567-4139-802b-518bcbd7bba7">7</a>)</span>].</p>
<p>Patients on concomitant CNS depressants must be monitored for a change in opioid effects. Consideration should be given to adjusting the dose of OTFC if warranted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8375e286-22ae-4e74-b368-ceff5d0cb58b"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Effects on Ability to Drive and Use Machines</h2>
<p class="First">Opioid analgesics impair the mental and/or physical ability required for the performance of potentially dangerous tasks (e.g., driving a car or operating machinery). Warn patients taking OTFC of these dangers and counsel them accordingly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4f3eb6a5-f2dd-4550-b4d8-e1c2a941f449"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Chronic Pulmonary Disease</h2>
<p class="First">Because potent opioids can cause <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, titrate OTFC with caution in patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> or preexisting medical conditions predisposing them to <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. In such patients, even normal therapeutic doses of OTFC may further decrease respiratory drive to the point of <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d1256612-965e-41fe-88f9-e20d255da009"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Head Injuries and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></h2>
<p class="First">Administer OTFC with extreme caution in patients who may be particularly susceptible to the intracranial effects of CO <span class="Sub">2</span> retention such as those with evidence of <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> or impaired consciousness. Opioids may obscure the clinical course of a patient with a <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span> and should be used only if clinically warranted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9eed5109-568c-40a4-a74f-04ab07aeb70e"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Cardiac Disease</h2>
<p class="First">Intravenous fentanyl may produce <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. Therefore, use OTFC with caution in patients with <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmias</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1e7e43c4-49af-4b7b-9eaa-e89559c7c23a"></a><a name="section-5.9"></a><p></p>
<h2>5.9 MAO Inhibitors</h2>
<p class="First">OTFC is not recommended for use in patients who have received MAO inhibitors within 14 days, because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-80726b26-6050-4911-b26b-bdc2f5fd4dc9"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access Program</h2>
<p class="First">Because of the risk for misuse, abuse, addiction, and <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> [See <span class="Bold">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></span> (<a href="#i4i_abuse_dependence_id_7f9b75a5-41cf-4e2f-b3d1-acb56d6da313">9</a>)], OTFC is available only through a restricted program called the TIRF REMS Access program.  Under the TIRF REMS Access program, outpatients, healthcare professionals who prescribe for outpatient use, pharmacies and distributors must enroll in the program. For inpatient administration, (e.g., hospitals, hospices, and long-term care facilities that prescribe for inpatient use) of OTFC, patient and prescriber enrollment is not required.</p>
<p>Required components of the TIRF REMS Access Program are:</p>
<dl>
<dt>â€¢</dt>
<dd>Healthcare professionals, who prescribe OTFC for outpatient use, must review the prescriber educational materials for the TIRF REMS Access Program, enroll in the program, and commit to comply with the REMS requirements.</dd>
<dt>â€¢</dt>
<dd>To receive OTFC, outpatients must understand the risks and benefits of the drug and sign a Patient-Prescriber Agreement.</dd>
<dt>â€¢</dt>
<dd>Pharmacies, that dispense OTFC, must enroll in the program, and agree to comply with the REMS requirements. </dd>
<dt>â€¢</dt>
<dd>Wholesalers and distributors, that distribute OTFC must enroll in the program, and distribute only to authorized enrolled pharmacies. </dd>
</dl>
<p>Further information, including a list of qualified pharmacies/distributors, is available at www.TIRFREMSAccess.com or by calling 1-866-822 1483.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_39dceb1a-05ee-45b9-8a3a-5bcc58168bba"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_57951dbc-f9b9-4f8f-b2d1-cce660703e3e"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">The safety of Oral Transmucosal Fentanyl Citrate (OTFC) has been evaluated in 257 opioid-tolerant chronic cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> patients. The duration of OTFC use varied during the open-label study. Some patients were followed for over 21 months. The average duration of therapy in the open-label study was 129 days.</p>
<p>The adverse reactions seen with OTFC are typical opioid side effects. Frequently, these adverse reactions will cease or decrease in intensity with continued use of OTFC, as the patient is titrated to the proper dose. Expect opioid side effects and manage them accordingly.</p>
<p>The most serious adverse reactions associated with all opioids including OTFC are <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (potentially leading to <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> or <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>), circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>. Follow all patients for symptoms of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
<p>Because the clinical trials of OTFC were designed to evaluate safety and efficacy in treating breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, all patients were also taking concomitant opioids, such as sustained-release morphine or transdermal fentanyl, for their persistent cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The adverse event data presented here reflect the actual percentage of patients experiencing each adverse effect among patients who received OTFC for breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> along with a concomitant opioid for persistent cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. There has been no attempt to correct for concomitant use of other opioids, duration of OTFC therapy, or cancer-related symptoms. Adverse reactions are included regardless of causality or severity.</p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>Three short-term clinical trials with similar titration schemes were conducted in 257 patients with malignancy and breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Data are available for 254 of these patients. The goal of titration in these trials was to find the dose of OTFC that provided adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> with acceptable side effects (successful dose). Patients were titrated from a low dose to a successful dose in a manner similar to current titration dosing guidelines. Table 1 lists, by dose groups, adverse reactions with an overall frequency of 1% or greater that occurred during titration and are commonly associated with opioid administration or are of particular clinical interest. The ability to assign a dose-response relationship to these adverse reactions is limited by the titration schemes used in these studies. Adverse reactions are listed in descending order of frequency within each body system.</p>
<a name="_Refid_00180928-021f-4373-b82d-aaddc9c1f"></a><table>
<caption><span>Table 1. Percent of Patients with Specific Adverse Events Commonly Associated with Opioid Administration or of Particular Clinical Interest Which Occurred During Titration (Events in 1% or More of Patients)</span></caption>
<col width="21%">
<col width="18%">
<col width="19%">
<col width="18%">
<col width="20%">
<col width="20%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Any Dose = A patient who experienced the same adverse event at multiple doses was only counted once</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2"><p class="First"><span class="Bold">Dose Group</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="5"><p class="First">Percentage of Patients Reporting Event</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">200-</span><br><span class="Bold">600 mcg (n=230)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">800-</span><br><span class="Bold">1400 mcg (n=138)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><br><span class="Bold">1600 mcg (n=54)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><br><span class="Bold">&gt; 1600 mcg (n=41)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Any Dose(n=254)</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Body As A Whole</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental Injury</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Digestive</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">14</p></td>
<td class="Botrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center"><p class="First">22</p></td>
<td class="Botrule Rrule" align="center"><p class="First">23</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Rrule" align="center"><p class="First">12</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Nervous</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">10</p></td>
<td class="Botrule Rrule" align="center"><p class="First">16</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Rrule" align="center"><p class="First">17</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center"><p class="First">20</p></td>
<td class="Botrule Rrule" align="center"><p class="First">17</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Abnormal Gait</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">Vasodilatation</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Thinking Abnormal</span>    </p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Respiratory</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Skin</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Special Senses</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">  <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal Vision</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
</tbody>
</table>
<p>The following adverse reactions not reflected in Table 1 occurred during titration with an overall frequency of 1% or greater and are listed in descending order of frequency within each body system.</p>
<p><span class="Bold">Body as a Whole: </span><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></p>
<p><span class="Bold">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></p>
<p><span class="Bold">Digestive: </span><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span></p>
<p><span class="Bold">Metabolic and Nutritional: </span><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span></p>
<p><span class="Bold">Nervous: </span><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypesthesia</span></p>
<p><span class="Bold">Respiratory: </span><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough increased</span></p>
<p>The following reactions occurred during titration with an overall frequency of less than 1% and are listed in descending order of frequency within each body system.</p>
<p><span class="Bold">Body as a Whole: </span><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu syndrome</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span></p>
<p><span class="Bold">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></p>
<p><span class="Bold">Digestive: </span><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="4268622" conceptname="Stricture of esophagus">esophageal stenosis</span>, <span class="product-label-link" type="condition" conceptid="4258683" conceptname="Fecal impaction">fecal impaction</span>, <span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">gum hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>, <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral moniliasis</span></p>
<p><span class="Bold">Hemic and Lymphatic: </span><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span></p>
<p><span class="Bold">Metabolic and Nutritional: </span><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span></p>
<p><span class="Bold">Musculoskeletal: </span><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>, <span class="product-label-link" type="condition" conceptid="73571" conceptname="Pathological fracture">pathological fracture</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">myasthenia</span></p>
<p><span class="Bold">Nervous: </span><span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">libido decreased</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, speech disorder</p>
<p><span class="Bold">Respiratory: </span><span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">Hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccup</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="318459" conceptname="Respiratory insufficiency">respiratory insufficiency</span>, <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> increased</p>
<p><span class="Bold">Skin and Appendages: </span><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span></p>
<p><span class="Bold">Special Senses: </span><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste perversion</span></p>
<p><span class="Bold">Urogenital: </span><span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></p>
<p>A long-term extension study was conducted in 156 patients with malignancy and breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> who were treated for an average of 129 days. Data are available for 152 of these patients. Table 2 lists by dose groups, adverse reactions with an overall frequency of 1% or greater that occurred during the long-term extension study and are commonly associated with opioid administration or are of particular clinical interest. Adverse reactions are listed in descending order of frequency within each body system.</p>
<a name="_Refid_3b6b93c3-3e65-482e-9ec1-4b5abf856"></a><table>
<caption><span>Â Table 2. Percent of Patients with Adverse Events Commonly Associated with Opioid Administration or of Particular Clinical Interest Which Occurred During Long Term Treatment (Events in 1% or More of Patients)</span></caption>
<col width="22%">
<col width="17%">
<col width="18%">
<col width="18%">
<col width="20%">
<col width="20%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Any Dose = A patient who experienced the same adverse event at multiple doses was only counted once</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2"><p class="First"><span class="Bold">Dose Group</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="5"><p class="First"><span class="Bold">Percentage of Patients Reporting Event</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">200-</span><br><span class="Bold">600 mcg (n=98)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">800-</span><br><span class="Bold">1400 mcg (n=83)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><br><span class="Bold">1600 mcg (n=53)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><br><span class="Bold">&gt;1600 mcg (n=27)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Any Dose(n=152)</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Body As A Whole</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">25</p></td>
<td class="Botrule Rrule" align="center"><p class="First">30</p></td>
<td class="Botrule Rrule" align="center"><p class="First">17</p></td>
<td class="Botrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Rrule" align="center"><p class="First">38</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center"><p class="First">17</p></td>
<td class="Botrule Rrule" align="center"><p class="First">13</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">20</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental Injury</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">Hypertonia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Digestive</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">31</p></td>
<td class="Botrule Rrule" align="center"><p class="First">36</p></td>
<td class="Botrule Rrule" align="center"><p class="First">25</p></td>
<td class="Botrule Rrule" align="center"><p class="First">26</p></td>
<td class="Botrule Rrule" align="center"><p class="First">45</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">21</p></td>
<td class="Botrule Rrule" align="center"><p class="First">28</p></td>
<td class="Botrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">31</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">14</p></td>
<td class="Botrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center"><p class="First">13</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">20</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Intestinal Obstruction</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Cardiovascular</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Nervous</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center"><p class="First">10</p></td>
<td class="Botrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">16</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">15</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">13</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">15</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">13</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">10</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Abnormal Gait</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">Stupor</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">Vasodilatation</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Thinking Abnormal</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal Dreams</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsion</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">Myoclonus</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Respiratory</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Rrule" align="center"><p class="First">16</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">22</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Skin</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Special Senses</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal Vision</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Urogenital</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
</tbody>
</table>
<p>Â The following reactions not reflected in Table 2 occurred with an overall frequency of 1% or greater in the long-term extension study and are listed in descending order of frequency within each body system.</p>
<p><span class="Bold">Body as a Whole: </span><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdomen enlarged</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>, <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span></p>
<p><span class="Bold">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">vascular disorder</span></p>
<p><span class="Bold">Digestive: </span><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral moniliasis</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>, <span class="product-label-link" type="condition" conceptid="79069" conceptname="Disorder of rectum">rectal disorder</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4103655" conceptname="Dental abscess">periodontal abscess</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span></p>
<p><span class="Bold">Hemic and Lymphatic: </span><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="435839" conceptname="Lymphedema">lymphedema</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span></p>
<p><span class="Bold">Metabolic and Nutritional: </span><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span></p>
<p><span class="Bold">Musculoskeletal: </span><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>, <span class="product-label-link" type="condition" conceptid="73571" conceptname="Pathological fracture">pathological fracture</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">joint disorder</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="75909" conceptname="Disorder of bone">bone disorder</span></p>
<p><span class="Bold">Nervous: </span><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypesthesia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, speech disorder</p>
<p><span class="Bold">Respiratory: </span><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough increased</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span> increased</p>
<p><span class="Bold">Skin and Appendages: </span><span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">Skin ulcer</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span></p>
<p><span class="Bold">Special Senses: </span><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="201577" conceptname="Degenerative and vascular disorders of ear">ear disorder</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span></p>
<p><span class="Bold">Urogenital: </span><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4230799" conceptname="Edema of scrotum">scrotal edema</span>, <span class="product-label-link" type="condition" conceptid="433811" conceptname="Hydronephrosis">hydronephrosis</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">urinary urgency</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">urination impaired</span>, breast neoplasm, <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> </p>
<p>The following reactions occurred with a frequency of less than 1% in the long-term extension study and are listed in descending order of frequency within each body system.</p>
<p><span class="Bold">Body as a Whole: </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4090433" conceptname="Flank pain">flank pain</span>, <span class="product-label-link" type="condition" conceptid="4163983" conceptname="Granuloma">granuloma</span>, <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>, <span class="product-label-link" type="condition" conceptid="4318379" conceptname="Disorder of mucous membrane">mucous membrane disorder</span>, <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">neck rigidity</span></p>
<p><span class="Bold">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disorder</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p>
<p><span class="Bold">Digestive: </span><span class="product-label-link" type="condition" conceptid="4301764" conceptname="Cheilitis">Cheilitis</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorder</span>, <span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">gum hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="442190" conceptname="Hemorrhage of colon">hemorrhage of colon</span>, <span class="product-label-link" type="condition" conceptid="196455" conceptname="Hepatorenal syndrome">hepatorenal syndrome</span>, <span class="product-label-link" type="condition" conceptid="4010482" conceptname="Liver tender">liver tenderness</span>, <span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">tooth caries</span>, <span class="product-label-link" type="condition" conceptid="4122115" conceptname="Tooth disorder">tooth disorder</span></p>
<p><span class="Bold">Hemic and Lymphatic: </span><span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">Bleeding time</span> increased</p>
<p><span class="Bold">Metabolic and Nutritional: </span><span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">Acidosis</span>, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span></p>
<p><span class="Bold">Musculoskeletal: </span><span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span>, <span class="product-label-link" type="condition" conceptid="78236" conceptname="Muscle atrophy">muscle atrophy</span>, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, <span class="product-label-link" type="condition" conceptid="4168183" conceptname="Synovitis">synovitis</span>, <span class="product-label-link" type="condition" conceptid="442264" conceptname="Disorder of tendon">tendon disorder</span></p>
<p><span class="Bold">Nervous: </span><span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">Acute brain syndrome</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span>, <span class="product-label-link" type="condition" conceptid="374923" conceptname="Bell's palsy">facial paralysis</span>, <span class="product-label-link" type="condition" conceptid="4264617" conceptname="Foot-drop">foot drop</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="374022" conceptname="Hemiplegia">hemiplegia</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="4318408" conceptname="Subdural hematoma">subdural hematoma</span></p>
<p><span class="Bold">Respiratory: </span><span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">Hiccup</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disorder</span>, <span class="product-label-link" type="condition" conceptid="253796" conceptname="Pneumothorax">pneumothorax</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">voice alteration</span></p>
<p><span class="Bold">Skin and Appendages: </span><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes zoster</span>, <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">vesiculobullous rash</span></p>
<p><span class="Bold">Special Senses: </span><span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">Ear pain</span>, <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">eye hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span> disorder, partial permanent <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="193210" conceptname="Transient ischemic deafness">partial transitory deafness</span></p>
<p><span class="Bold">Urogenital: </span><span class="product-label-link" type="condition" conceptid="4167250" conceptname="Renal pain">Kidney pain</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelonephritis</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_12b59e12-0590-43a8-a2f7-c346a69e8436"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-Marketing Experience</h2>
<p class="First">Adverse reactions are reported voluntarily from a population of uncertain size, and, therefore, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of the reporting, or (3) strength of causal connection to OTFC <span class="Italics">.</span></p>
<p>The following adverse reactions have been identified during post-approval use of OTFC (which contains approximately 2 grams of sugar per unit):</p>
<p><span class="Bold">Digestive: </span><span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">Dental decay</span> of varying severity including <span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">dental caries</span>, <span class="product-label-link" type="condition" conceptid="433244" conceptname="Tooth loss">tooth loss</span>, and gum line erosion.</p>
<p><span class="Bold">General Disorders and Administration Site Conditions: </span><span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application site reactions</span> including irritation, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_37e8901a-4567-4139-802b-518bcbd7bba7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Fentanyl is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4); therefore potential interactions may occur when OTFC is given concurrently with agents that affect CYP3A4 activity. The concomitant use of OTFC with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazodone) or moderate CYP3A4 inhibitors (e.g., amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, and verapamil) may result in increased fentanyl plasma concentrations, potentially causing serious adverse drug effects including fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Patients receiving OTFC concomitantly with moderate or strong CYP3A4 inhibitors should be carefully monitored for an extended period of time. Dosage increase should be done conservatively.</p>
<p>Grapefruit and grapefruit juice decrease CYP3A4 activity, increasing blood concentrations of fentanyl, thus should be avoided.</p>
<p>Drugs that induce cytochrome P450 3A4 activity may have the opposite effects.</p>
<p>Concomitant use of OTFC with an MAO inhibitor, or within 14 days of discontinuation, is not recommended [ <span class="Italics">see Warnings And Precautions (<a href="#i4i_section_id_1e7e43c4-49af-4b7b-9eaa-e89559c7c23a">5.9</a>)</span>]<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_44203923-e23b-4abf-ab80-78588ebb1f19"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_ce9376e2-feda-4dc2-9c6a-bca2b5f49114"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C</p>
<p>There are no adequate and well-controlled studies in pregnant women. Oral Transmucosal Fentanyl Citrate (OTFC) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. No epidemiological studies of congenital anomalies in infants born to women treated with fentanyl during pregnancy have been reported.</p>
<p>Chronic maternal treatment with fentanyl during pregnancy has been associated with transient <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, behavioral changes, or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in newborn infants characteristic of neonatal abstinence syndrome.</p>
<p>In women treated acutely with intravenous or epidural fentanyl during labor, symptoms of neonatal respiratory or neurological <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> were no more frequent than would be expected in infants of untreated mothers.</p>
<p>Transient neonatal muscular <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span> has been observed in infants whose mothers were treated with intravenous fentanyl.</p>
<p>Fentanyl is embryocidal in rats as evidenced by increased resorptions in pregnant rats at doses of 30 mcg/kg IV or 160 mcg/kg SC. Conversion to human equivalent doses indicates this is within the range of the human recommended dosing for OTFC.</p>
<p>Fentanyl citrate was not teratogenic when administered to pregnant animals. Published studies demonstrated that administration of fentanyl (10, 100, or 500 mcg/kg/day) to pregnant rats from day 7 to 21, of their 21 day gestation, via implanted microosmotic minipumps was not teratogenic (the high dose was approximately 3-times the human dose of 1600 mcg per <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> episode on a mg/m <span class="Sup">2</span> basis). Intravenous administration of fentanyl (10 or 30 mcg/kg) to pregnant female rats from gestation day 6 to 18, was embryo or fetal toxic, and caused a slightly increased mean delivery time in the 30 mcg/kg/day group, but was not teratogenic.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_8ccc5456-9142-4bd3-9c63-a2fe205fa585"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">Fentanyl readily passes across the placenta to the fetus; therefore do not use OTFC during labor and delivery (including caesarean section) since it may cause <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the fetus or in the newborn infant.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_4aa241c4-269c-4b2e-87a1-e8c2499e4815"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Fentanyl is excreted in human milk; therefore, do not use OTFC in nursing women because of the possibility of sedation and/or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in their infants. Symptoms of opioid withdrawal may occur in infants at the cessation of nursing by women using OTFC.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_d4f9e45e-b5d3-4ce6-a77a-bdf8b52d14a6"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients below 16 years of age have not been established.</p>
<p>In a clinical study, 15 opioid-tolerant pediatric patients with breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, ranging in age from 5 to 15 years, were treated with OTFC. The study was too small to allow conclusions on safety and efficacy in this patient population. Twelve of the fifteen opioid-tolerant children and adolescents aged 5 to 15 years in this study received OTFC at doses ranging from 200 mcg to 600 mcg. The mean (CV%; range) dose-normalized (to 200 mcg) C <span class="Sub">max</span> and AUC<span class="Sub">0-8</span> values were 0.87 ng/mL (51%; 0.42-1.30) and 4.54 ngâ‹…h/mL (42%; 2.37-6.0), respectively, for children ages 5 to &lt;11 years old (N = 3) and 0.68 ng/mL (72%; 0.15-1.44) and 8.38 (192%; 0.84-50.78), respectively, for children ages â‰¥11 to &lt;16 y (N = 9). </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_f66f5894-ed27-47c8-88a3-49ca5007a7b2"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 257 patients in clinical studies of OTFC in breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, 61 (24%) were 65 years of age and older, while 15 (6%) were 75 years of age and older. Those patients over the age of 65 years were titrated to a mean dose that was about 200 mcg less than the mean dose titrated to by younger patients. No difference was noted in the safety profile of the group over 65 years of age as compared to younger patients in OTFC clinical trials.</p>
<p>Elderly patients have been shown to be more sensitive to the effects of fentanyl when administered intravenously, compared with the younger population. Therefore, exercise caution when individually titrating OTFC in elderly patients to provide adequate efficacy while minimizing risk.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5e93a67f-2d49-4030-b2fd-3277ad1f99aa"></a><a name="section-8.6"></a><p></p>
<h2>8.6 Patients with Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Insufficient information exists to make recommendations regarding the use of OTFC in patients with impaired renal or hepatic function. Fentanyl is metabolized primarily via human cytochrome P450 3A4 isoenzyme system and mostly eliminated in urine. If the drug is used in these patients, it should be used with caution because of the hepatic metabolism and renal excretion of fentanyl.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7c67c388-f48e-42eb-91d7-f5744fd093a3"></a><a name="section-8.7"></a><p></p>
<h2>8.7 Gender</h2>
<p class="First">Both male and female opioid-tolerant cancer patients were studied for the treatment of breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. No clinically relevant gender differences were noted either in dosage requirement or in observed adverse reactions.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_id_7f9b75a5-41cf-4e2f-b3d1-acb56d6da313"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="i4i_controlled_substance_id_339d7edc-255c-48e0-b2aa-a166a17c9919"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance</h2>
<p class="First">Fentanyl is a Schedule II controlled substance that can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the morphine type. Oral Transmucosal Fentanyl Citrate (OTFC) may be subject to misuse, abuse and addiction.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="i4i_abuse_id_5dbb7bd0-76c0-43e4-b2c8-f42f0c2e05db"></a><a name="section-9.2"></a><p></p>
<h2>9.2 Abuse and Addiction</h2>
<p class="First">Manage the handling of OTFC to minimize the risk of diversion, including restriction of access and accounting procedures as appropriate to the clinical setting and as required by law [s <span class="Italics">ee How Supplied/Storage and Handling (<a href="#i4i_section_id_c9569ac2-f8e5-492d-b4ee-67300f5e78a9">16.1</a>, <a href="#i4i_section_id_4fc9421d-5313-423c-b4e4-b0a17d756de0">16.2</a>)</span>].</p>
<p>Concerns about abuse, addiction, and diversion should not prevent the proper management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. However, all patients treated with opioids require careful monitoring for signs of abuse and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use.</p>
<p>Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is a treatable disease, utilizing a multidisciplinary approach, but relapse is common. â€œDrug-seekingâ€? behavior is very common in addicts and drug abusers.</p>
<p>Abuse and addiction are separate and distinct from physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance. Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> in all addicts. In addition, abuse of opioids can occur in the absence of addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances. Since OTFC may be diverted for non-medical use, careful record keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised.</p>
<p>Proper assessment of patients, proper prescribing practices, periodic reevaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.</p>
<p>Healthcare professionals should contact their State Professional Licensing Board, or State Controlled Substances Authority for information on how to prevent and detect abuse or diversion of this product.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="i4i_dependence_id_51e7fa5a-8f9d-43f6-afc9-54892be083aa"></a><a name="section-9.3"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Guide the administration of OTFC by the response of the patient. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, per se, is not ordinarily a concern when one is treating a patient with chronic cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="4029621" conceptname="Fear">fear</span> of tolerance and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> should not deter using doses that adequately relieve the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p>Opioid analgesics may cause physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> results in withdrawal symptoms in patients who abruptly discontinue the drug. Withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity, e.g., naloxone, nalmefene, or mixed agonist/antagonist analgesics (pentazocine, butorphanol, buprenorphine, nalbuphine).</p>
<p>Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> usually does not occur to a clinically significant degree until after several weeks of continued opioid usage. Tolerance, in which increasingly larger doses are required in order to produce the same degree of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, is initially manifested by a shortened duration of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span>, and subsequently, by decreases in the intensity of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_10a79d19-f22d-4f8e-89b2-c0ee00e1b289"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2d6e5c6b-2ff1-4408-b258-4c0c93671e0a"></a><a name="section-10.1"></a><p></p>
<h2>10.1 Clinical Presentation</h2>
<p class="First">The manifestations of Oral Transmucosal Fentanyl Citrate (OTFC) overdosage are expected to be similar in nature to intravenous fentanyl and other opioids, and are an extension of its pharmacological actions with the most serious significant effect being <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> [ <span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacodynamics_id_6311026d-9c89-4486-aad2-b9ea2c5cf59f">12.2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7fbfa33f-a546-4929-a7fa-4cbc55798335"></a><a name="section-10.2"></a><p></p>
<h2>10.2 Immediate Management</h2>
<p class="First">Immediate management of opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> includes removal of the OTFC unit, if still in the mouth, ensuring a patent airway, physical and verbal stimulation of the patient, and assessment of level of consciousness, ventilatory and circulatory status.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_217dffd2-88bc-46fe-8401-37530da82a74"></a><a name="section-10.3"></a><p></p>
<h2>10.3 Treatment of Overdosage (Accidental Ingestion) in the Opioid NON-Tolerant Person</h2>
<p class="First">Provide ventilatory support, obtain intravenous access, and employ naloxone or other opioid antagonists as clinically indicated. The duration of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> following <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may be longer than the effects of the opioid antagonistâ€™s action (e.g., the half-life of naloxone ranges from 30 to 81 minutes) and repeated administration may be necessary. Consult the package insert of the individual opioid antagonist for details about such use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_122f2261-922d-483a-9ee5-16b459598eba"></a><a name="section-10.4"></a><p></p>
<h2>10.4 Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> in Opioid-Tolerant Patients</h2>
<p class="First">Provide ventilatory support and obtain intravenous access as clinically indicated. Judicious use of naloxone or another opioid antagonist may be warranted in some instances, but it is associated with the risk of precipitating an acute withdrawal syndrome.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e930418e-6ad4-46b8-badc-2cc93aa6badf"></a><a name="section-10.5"></a><p></p>
<h2>10.5 General Considerations for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></h2>
<p class="First">Management of severe OTFC <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> includes: securing a patent airway, assisting or controlling ventilation, establishing intravenous access, and GI decontamination by lavage and/or activated charcoal, once the patientâ€™s airway is secure. In the presence of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> or <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, assist or control ventilation, and administer oxygen as indicated.</p>
<p>Although <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span> interfering with respiration has not been seen following the use of OTFC, this is possible with fentanyl and other opioids. If it occurs, manage it by using assisted or controlled ventilation, by an opioid antagonist, and as a final alternative, by a neuromuscular blocking agent.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_8d00c812-3ce3-4f04-a1ee-37a20b7f06d4"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Oral Transmucosal Fentanyl Citrate (OTFC) is a solid formulation of fentanyl citrate, a potent opioid analgesic, intended for oral transmucosal administration. OTFC is formulated as a white to off-white solid drug matrix on a handle that is <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> resistant (ABS plastic) under normal conditions when used as directed.</p>
<p>OTFC is designed to be dissolved slowly in the mouth to facilitate transmucosal absorption. The handle allows the OTFC unit to be removed from the mouth if signs of excessive opioid effects appear during administration.</p>
<p>Fentanyl citrate, USP is N-(1-Phenethyl-4-piperidyl) propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic solvents and sparingly soluble in water (1:40). The molecular weight of the free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens are 7.3 and 8.4. The compound has the following structural formula:</p>
<div class="Figure"><img alt="this is the structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-03.jpg"></div>
<p><span class="Bold">Inactive Ingredients: </span>Anhydrous citric acid, artificial raspberry flavor, confectionerâ€™s sugar, dextrates, dibasic sodium phosphate, FD&amp;C blue no. 1, magnesium stearate, pregelatinized starch, propylene glycol and purified shellac.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_955e4c08-a97a-492d-9418-11c3adb62135"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_8b1530ad-0c91-42fa-b3cb-e0d774d75c34"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Fentanyl is a pure opioid agonist whose principal therapeutic action is <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_6311026d-9c89-4486-aad2-b9ea2c5cf59f"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Pharmacological effects of opioid agonists include anxiolysis, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, feelings of relaxation, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="4009383" conceptname="Cough suppression">cough suppression</span>, and <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. Like all pure opioid agonist analgesics, with increasing doses there is increasing <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, unlike with mixed agonist/antagonists or non-opioid analgesics, where there is a limit to the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> with increasing doses. With pure opioid agonist analgesics, there is no defined maximum dose; the ceiling to analgesic effectiveness is imposed only by side effects, the more serious of which may include <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span></span></p>
<p>The <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effects</span> of fentanyl are related to the blood level of the drug, if proper allowance is made for the delay into and out of the CNS (a process with a 3- to 5-minute half-life).</p>
<p>In general, the effective concentration and the concentration at which toxicity occurs increase with increasing tolerance with any and all opioids. The rate of development of tolerance varies widely among individuals. As a result, the dose of Oral Transmucosal Fentanyl Citrate (OTFC) should be individually titrated to achieve the desired effect [ <span class="Italics">see Dosage And Administration (<a href="#i4i_section_id_71e511e7-9665-4959-bbaf-0a99ae9605e7">2.2</a>)</span>].</p>
<p><span class="Underline">Central Nervous System</span></p>
<p>The precise mechanism of the analgesic action is unknown although fentanyl is known to be a <span class="Italics">mu-</span>opioid receptor agonist. Specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and play a role in the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effects</span> of this drug.</p>
<p>Fentanyl produces <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> by direct action on brain stem respiratory centers. The <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> involves both a reduction in the responsiveness of the brain stem to increases in <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> and to electrical stimulation.</p>
<p>Fentanyl depresses the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex by direct effect on the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> center in the medulla. Antitussive effects may occur with doses lower than those usually required for <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.</p>
<p>Fentanyl causes <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> even in total darkness. Pinpoint pupils are a sign of opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origin may produce similar findings).</p>
<p><span class="Underline">Gastrointestinal System</span></p>
<p>Fentanyl causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and in the duodenum. Digestion of food is delayed in the small intestine and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm resulting in <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Other opioid-induced effects may include a reduction in gastric, biliary and pancreatic secretions, spasm of the sphincter of Oddi, and transient elevations in serum amylase.</p>
<p><span class="Underline">Cardiovascular System</span></p>
<p>Fentanyl may produce release of histamine with or without associated peripheral vasodilation. Manifestations of histamine release and/or peripheral vasodilation may include <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">red eyes</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, and/or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>.</p>
<p><span class="Underline">Endocrine System</span></p>
<p>Opioid agonists have been shown to have a variety of effects on the secretion of hormones. Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans. They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs. Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.</p>
<p><span class="Underline">Respiratory System</span></p>
<p>All opioid <span class="Italics">mu</span>-receptor agonists, including fentanyl, produce dose-dependent <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. The risk of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> is less in patients receiving chronic opioid therapy who develop tolerance to <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and other opioid effects. During the titration phase of the clinical trials, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, which may be a precursor to <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, did increase in patients who were treated with higher doses of OTFC. Peak respiratory depressive effects may be seen as early as 15 to 30 minutes from the start of oral transmucosal fentanyl citrate product administration and may persist for several hours.</p>
<p>Serious or fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> can occur even at recommended doses. Fentanyl depresses the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex as a result of its CNS activity. Although not observed with oral transmucosal fentanyl products in clinical trials, fentanyl given rapidly by intravenous injection in large doses may interfere with respiration by causing <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span> in the muscles of respiration. Therefore, physicians and other healthcare providers should be aware of this potential complication [ <span class="Italics">see Boxed Warning - Warning: Risk of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span>, Medication Errors, Abuse Potential<span class="Bold">, </span>Contraindications (<a href="#i4i_contraindications_id_73c75da0-5a3e-48db-9829-84bcdc4700c4">4</a>)Â </span><span class="Bold">, </span><span class="Italics">Warnings And Precautions(<a href="#_Ref">5.2</a>)Â </span><span class="Bold">, </span><span class="Italics">Adverse Reactions (<a href="#i4i_adverse_effects_id_39dceb1a-05ee-45b9-8a3a-5bcc58168bba">6</a>)<span class="Bold">, </span>and Overdosage (<a href="#i4i_overdosage_id_10a79d19-f22d-4f8e-89b2-c0ee00e1b289">10</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_ebfe50d2-6256-44d9-85dc-c1608b418ac8"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Underline">Absorption</span></p>
<p>The absorption pharmacokinetics of fentanyl from the oral transmucosal dosage form is a combination of an initial rapid absorption from the buccal mucosa and a more prolonged absorption of swallowed fentanyl from the GI tract. Both the blood fentanyl profile and the bioavailability of fentanyl will vary depending on the fraction of the dose that is absorbed through the oral mucosa and the fraction swallowed.</p>
<p>Absolute bioavailability, as determined by area under the concentration-time curve, of 15 mcg/kg in 12 adult males was 50% compared to intravenous fentanyl.</p>
<p>Normally, approximately 25% of the total dose of Oral Transmucosal Fentanyl Citrate (OTFC) is rapidly absorbed from the buccal mucosa and becomes systemically available. The remaining 75% of the total dose is swallowed with the saliva and then is slowly absorbed from the GI tract. About 1/3 of this amount (25% of the total dose) escapes hepatic and intestinal first-pass elimination and becomes systemically available. Thus, the generally observed 50% bioavailability of OTFC is divided equally between rapid transmucosal and slower GI absorption. Therefore, a unit dose of OTFC, if chewed and swallowed, might result in lower peak concentrations and lower bioavailability than when consumed as directed.</p>
<p>Dose proportionality among four of the available strengths of OTFC (200, 400, 800, and 1600 mcg) has been demonstrated in a balanced crossover design in adult subjects (n=11). Mean serum fentanyl levels following these four doses of OTFC are shown in Figure 1. The curves for each dose level are similar in shape with increasing dose levels producing increasing serum fentanyl levels. C <span class="Sub">max</span> and AUC<span class="Sub">0â†’âˆž</span> increased in a dose-dependent manner that is approximately proportional to the OTFC administered.</p>
<div class="Figure"><img alt="this is figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-04.jpg"></div>
<p>The pharmacokinetic parameters of the four strengths of OTFC tested in the dose-proportionality study are shown in Table 3. The mean C <span class="Sub">max</span> ranged from 0.39 to 2.51 ng/mL. The median time of maximum plasma concentration (T<span class="Sub">max</span>) across these four doses of OTFC varied from 20 to 40 minutes (range of 20 to 480 minutes) as measured after the start of administration.</p>
<a name="_Refid_eda3180f-a558-464c-94d2-c3a0f5191"></a><table>
<caption><span>Table 3. Pharmacokinetic Parameters<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a> in Adult Subjects Receiving 200, 400, 800, and 1600 mcg Units of OTFC</span></caption>
<colgroup>
<col width="29%">
<col width="22%">
<col width="22%">
<col width="21%">
<col width="22%">
</colgroup>
<tfoot>
<tr class="First Last"><td class="Footnote" align="left"></td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd> based on arterial blood samples.</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Pharmacokinetic Parameter</span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><br><span class="Bold">200 mcg</span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">400 mcg</span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">800 mcg</span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">1600 mcg</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">T<span class="Sub">max</span>, minute median (range)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">(20 to 120)40</p></td>
<td class="Botrule Rrule" align="center"><p class="First">(20 to 240)25</p></td>
<td class="Botrule Rrule" align="center"><p class="First">(20 to120)25</p></td>
<td class="Botrule Rrule" align="center"><p class="First">(20 to 480)20</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">C<span class="Sub">max</span>, ng/mL mean (%CV)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.39 (23)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.75 (33)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.55 (30)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.51 (23)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">mean (%CV)AUC <span class="Sub"> 0-1440</span> , ng/mL minute</p></td>
<td class="Botrule Rrule" align="center"><p class="First">102 (65)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">243 (67)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">573 (64)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1026 (67)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">t<span class="Sub">Â½ </span>, minute mean (%CV)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">193 (48)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">386 (115)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">381 (55)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">358 (45)</p></td>
</tr>
</tbody>
</table>
<p></p>
<p><span class="Underline">Distribution</span></p>
<p>Fentanyl is highly lipophilic. Animal data showed that following absorption, fentanyl is rapidly distributed to the brain, heart, lungs, kidneys and spleen followed by a slower redistribution to muscles and fat. The plasma protein binding of fentanyl is 80 to 85%. The main binding protein is alpha-1-acid glycoprotein, but both albumin and lipoproteins contribute to some extent. The free fraction of fentanyl increases with <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>. The mean volume of distribution at steady-state (Vss) was 4 L/kg.</p>
<p><span class="Underline">Metabolism</span></p>
<p>Fentanyl is metabolized in the liver and in the intestinal mucosa to norfentanyl by cytochrome P450 3A4 isoform. Norfentanyl was not found to be pharmacologically active in animal studies [ <span class="Italics">see Drug Interactions (<a href="#i4i_interactions_id_37e8901a-4567-4139-802b-518bcbd7bba7">7</a>)</span>].</p>
<p><span class="Underline">Elimination</span></p>
<p>Fentanyl is primarily (more than 90%) eliminated by biotransformation to N-dealkylated and hydroxylated inactive metabolites. Less than 7% of the dose is excreted unchanged in the urine, and only about 1% is excreted unchanged in the feces. The metabolites are mainly excreted in the urine, while fecal excretion is less important. The total plasma clearance of fentanyl was 0.5 L/hr/kg (range 0.3 to 0.7 L/hr/kg). The terminal elimination half-life after OTFC administration is about 7 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_d0ff55b4-3c7b-4847-9dc4-b3661c55639d"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_9e6fe603-e7e2-4173-9992-208f3886ef46"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals have not been performed to evaluate the carcinogenic potential of fentanyl.</p>
<p>Fentanyl citrate was not mutagenic in the <span class="Italics">in vitro </span>Ames reverse mutation assay in <span class="Italics">S. typhimurium </span>or <span class="Italics">E. coli</span>, or the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> mutagenesis assay, and was not clastogenic in the <span class="Italics">in vivo </span>mouse micronucleus assay.</p>
<p>Fentanyl has been shown to impair fertility in rats at doses of 30 mcg/kg IV and 160 mcg/kg subcutaneously. Conversion to the human equivalent doses indicates that this is within the range of the human recommended dosing for OTFC.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_0108e8b2-ad22-427a-a9ce-9745e52da14a"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Oral Transmucosal Fentanyl Citrate (OTFC) was investigated in clinical trials involving 257 opioid tolerant adult cancer patients experiencing breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> was defined as a transient flare of moderate-to-severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> occurring in cancer patients experiencing persistent cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> otherwise controlled with maintenance doses of opioid medications including at least 60 mg morphine/day, 50 mcg transdermal fentanyl/hour, or an equianalgesic dose of another opioid for a week or longer.</p>
<p>In two dose titration studies 95 of 127 patients (75%) who were on stable doses of either long-acting oral opioids or transdermal fentanyl for their persistent cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> titrated to a successful dose of OTFC to treat their breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> within the dose range offered (200, 400, 600, 800, 1200 and 1600 mcg). A â€œsuccessfulâ€? dose was defined as a dose where one unit of OTFC could be used consistently for at least two consecutive days to treat breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> without unacceptable side effects. In these studies 11% of patients withdrew due to adverse reactions and 14% withdrew due to other reasons.</p>
<p>The successful dose of OTFC for breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> was not predicted from the daily maintenance dose of opioid used to manage the persistent cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and is thus best determined by dose titration.</p>
<p>A double-blind placebo controlled crossover study was performed in cancer patients to evaluate the effectiveness of OTFC for the treatment of breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Of 130 patients who entered the study 92 patients (71%) achieved a successful dose during the titration phase. The distribution of successful doses is shown in Table 4.</p>
<a name="_Refid_02928c29-fd79-4df4-ae50-daa3d6cb8"></a><table>
<caption><span>Table 4. Successful Dose of OTFC Following Initial Titration</span></caption>
<colgroup>
<col width="14%">
<col width="22%">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">OTFC Dose</span></p></td>
<td class="Botrule Rrule Toprule"><p class="First">Total No. (%)(N=92)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">200 mcg</p></td>
<td class="Botrule Rrule"><p class="First">13 (14)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">400 mcg</p></td>
<td class="Botrule Rrule"><p class="First">19 (21)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">600 mcg</p></td>
<td class="Botrule Rrule"><p class="First">14 (15)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">800 mcg</p></td>
<td class="Botrule Rrule"><p class="First">18 (20)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">1200 mcg</p></td>
<td class="Botrule Rrule"><p class="First">13 (14)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">1600 mcg</p></td>
<td class="Botrule Rrule"><p class="First">15 (16)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Mean +/- SD</p></td>
<td class="Botrule Rrule"><p class="First">789 +/- 468 mcg</p></td>
</tr>
</tbody>
</table>
<p>Â On average, patients over 65 years of age titrated to a mean dose that was about 200 mcg less than the mean dose to which younger adult patients were titrated.</p>
<p>OTFC was administered beginning at Time 0 minutes and produced more <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief compared with placebo at 15, 30, 45, and 60 minutes as measured after the start of administration (see Figure 2). The differences were statistically significant.</p>
<p><span class="Bold">Figure 2. <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Relief (PR) Scores (Mean Â± SD) During the Double â€“Blind Phase All Patients with Evaluable Episodes on Both OTFC and Placebo (N=86)</span></p>
<div class="Figure"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-05.jpg"></div>
<p>* P-values &lt;0.0001 <span class="Sup"> 1</span></p>
<p>0 minutes = Start of administration of OTFC Â </p>
<p><span class="Sup">2</span> 15 minutes = First time to measure <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_69bd456b-f904-43ab-b2a0-6ed2ea1264e8"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c9569ac2-f8e5-492d-b4ee-67300f5e78a9"></a><a name="section-15.1"></a><p></p>
<h2>16.1 Storage and Handling</h2>
<p class="First">Oral Transmucosal Fentanyl Citrate (OTFC) is supplied in individually sealed child-resistant <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages. The amount of fentanyl contained in OTFC can be fatal to a child. Patients and their caregivers must be instructed to keep OTFC out of the reach of children [ <span class="Italics">see Boxed Warning - Warning: Risk of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span>, Medication Errors, Abuse Potential, Warnings And Precautions (<a href="#i4i_section_id_b3a6c75f-d023-4300-aa81-f10ab5c83776">5.2</a>)</span>, <span class="Italics">and Patient Counseling Information (<a href="#i4i_section_id_3f25afa4-20fc-43c2-a0f1-1ed077c64f5d">17.1</a>)</span>].</p>
<p>Store at 20Â° to 25ÂºC (68Â° to 77ÂºF) [See USP Controlled Room Temperature] until ready to use. Protect OTFC from freezing and moisture. Do not use if the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package has been opened.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4fc9421d-5313-423c-b4e4-b0a17d756de0"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Disposal of OTFC</h2>
<p class="First">Patients must be advised to dispose of any units remaining from a prescription as soon as they are no longer needed. While all units should be disposed of immediately after use, partially consumed units represent a special risk because they are no longer protected by the child-resistant <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package, yet may contain enough medicine to be fatal to a child [ <span class="Italics">see Patient Counseling Information (<a href="#i4i_section_id_feae8f98-4804-4c17-ae0b-e6a86c38da38">17.5</a>)</span>].</p>
<p>A temporary storage bottle is provided as part of the Oral Transmucosal Fentanyl Citrate (OTFC) Child Safety Kit [ <span class="Italics">see Patient Counseling Information (<a href="#i4i_section_id_d65817e7-0812-4b04-8b1f-63f8fa54bf73">17.4</a>)</span>]. This container is to be used by patients or their caregivers in the event that a partially consumed unit cannot be disposed of promptly. Instructions for usage of this container are included in the <span class="Italics">Medication Guide</span>.</p>
<p>Patients and members of their household must be advised to dispose of any units remaining from a prescription as soon as they are no longer needed. Instructions are included in <span class="Italics">Patient Counseling Information (<a href="#i4i_section_id_b7e38cb6-bc87-43bc-9bb2-451a47cec132">17.6</a>) </span>and in the <span class="Italics">Medication Guide</span>. If additional assistance is required, call PAR PHARMACEUTICAL 1-800-828-9393.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_50e11a2a-022d-4627-bd40-08190ed75945"></a><a name="section-15.3"></a><p></p>
<h2>16.3 How Supplied</h2>
<p class="First">Oral Transmucosal Fentanyl Citrate (OTFC) is supplied in six dosage strengths. Each unit is individually wrapped in a child-resistant, protective <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package. These <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages are packed 30 per shelf carton for use when patients have been titrated to the appropriate dose.</p>
<p>Each dosage unit has a white to off-white color. Each individual solid drug matrix is marked with â€œFentanylâ€? and the strength of the unit (â€œ200 mcgâ€?, â€œ400 mcgâ€?, â€œ600 mcgâ€?, â€œ800 mcgâ€? ,â€œ1200 mcgâ€?, or â€œ1600 mcgâ€?). The dosage strength is also marked on the handle tag, the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package and the carton. See <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package and carton for product information.</p>
<p>Oral Transmucosal Fentanyl Citrate (OTFC) is supplied as white to off-white, round cylindrical shaped lozenges attached to a <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> resistant plastic handle, as:</p>
<p>200 mcg: Imprinted Fentanyl over 200 mcg in blue ink, debossed with 1 on the convex (top) side and flat on the other (bottom) side.</p>
<p>30 Units (10 x 3 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span>)</p>
<p>400 mcg: Imprinted Fentanyl over 400 mcg in blue ink, debossed with 2 on the convex (top) side and flat on the other (bottom) side.</p>
<p>30 Units (10 x 3 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span>)</p>
<p>600 mcg: Imprinted Fentanyl over 600 mcg in blue ink, debossed with 3 on the convex (top) side and flat on the other (bottom) side.</p>
<p>30 Units (10 x 3 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span>)</p>
<p>800 mcg: Imprinted Fentanyl over 800 mcg in blue ink, debossed with 4 on the convex (top) side and flat on the other (bottom) side.</p>
<p>30 Units (10 x 3 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span>)</p>
<p>1200 mcg: Imprinted Fentanyl over 1200 mcg in blue ink, debossed with 5 on the convex (top) side and flat on the other (bottom) side.</p>
<p>30 Units (10 x 3 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span>)</p>
<p>1600 mcg: Imprinted Fentanyl over 1600 mcg in blue ink, debossed with 6 on the convex (top) side and flat on the other (bottom) side.</p>
<p>30 Units (10 x 3 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span>)</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_6621b89e-8138-4cb6-a63b-46577a24d87d"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labeling ( <span class="Italics">Medication Guide</span>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3f25afa4-20fc-43c2-a0f1-1ed077c64f5d"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Patient/Caregiver Instructions</h2>
<dl>
<dt></dt>
<dd><dl>
<dt>âˆ˜</dt>
<dd>Outpatients must be enrolled in the TIRF REMS Access program  before they can receive OTFC.</dd>
<dt>âˆ˜</dt>
<dd>Allow patients the opportunity to ask questions and discuss any concerns regarding OTFC or the TIRF REMS Access program.</dd>
<dt>âˆ˜</dt>
<dd>As a component of the TIRF REMS Access Program, prescribers must review the contents of the OTFC Medication Guide with every patient before initiating treatment with OTFC.</dd>
<dt>âˆ˜</dt>
<dd>Advise the patient that OTFC is available only from pharmacies that are enrolled in the TIRF REMS Access program, and provide them with the telephone number and website for information on how to obtain the drug.</dd>
<dt>âˆ˜</dt>
<dd>Advise the patient that only enrolled healthcare providers may prescribe OTFC.</dd>
<dt>âˆ˜</dt>
<dd>Patient must sign the Patient-Prescriber Agreement to acknowledge that they understand the risks of OTFC.</dd>
<dt>âˆ˜</dt>
<dd>Advise patients that they may be requested to participate in a survey to evaluate the effectiveness of the TIRF REMS Access program.</dd>
</dl></dd>
<dt>1.</dt>
<dd>
<span class="Bold">Patients and their caregivers must be instructed that children exposed to OTFC are at high risk of FATAL <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>. </span>Patients and their caregivers must be instructed to keep OTFC out of the reach of children [<span class="Italics">See How Supplied/Storage And Handling (<a href="#i4i_section_id_c9569ac2-f8e5-492d-b4ee-67300f5e78a9">16.1</a>), Warnings And Precautions (<a href="#_Ref">5.2</a> and <a href="#i4i_section_id_6b0f9ad8-fdbe-4f32-92c1-a012f09eb7be">5.3</a>) and Medication Guide for specific patient instructions.</span>]Â  </dd>
<dt>2.</dt>
<dd>Provide patients and their caregivers with a Medication Guide and review it with them each time OTFC is dispensed because new information may be available. </dd>
<dt>3.</dt>
<dd>Instruct patients and their caregivers to keep both used and unused dosage units out of the reach of children. Partially consumed units represent a special risk to children. In the event that a unit is not completely consumed it must be properly disposed as soon as possible [<span class="Italics">see How Supplied/Storage And Handling (<a href="#i4i_section_id_c9569ac2-f8e5-492d-b4ee-67300f5e78a9">16.1</a>), Warnings And Precautions (<a href="#i4i_section_id_6b0f9ad8-fdbe-4f32-92c1-a012f09eb7be">5.3</a>), and Patient Counseling Information (<a href="#i4i_section_id_feae8f98-4804-4c17-ae0b-e6a86c38da38">17.5</a>)</span>]. </dd>
<dt>4.</dt>
<dd>Instruct patients not to take OTFC for <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span>, <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from injuries, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or any other short-term <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, even if they have taken other opioid analgesics for these conditions. </dd>
<dt>5.</dt>
<dd>Instruct patients on the meaning of opioid tolerance and that OTFC is only to be used as a supplemental <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medication for patients with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> requiring around-the-clock opioids, who have developed tolerance to the opioid medication, and who need additional opioid treatment of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> episodes. </dd>
<dt>6.</dt>
<dd>Instruct patients that, if they are not taking an opioid medication on a scheduled basis (around-the-clock), they should not take OTFC. </dd>
<dt>7.</dt>
<dd>Instruct patients that, if the breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> episode is not relieved 15 minutes after finishing the OTFC unit, they may take <span class="Bold">ONLY ONE ADDITIONAL UNIT OF OTFC USING THE SAME STRENGTH FOR THAT EPISODE. Thus, patients should take no more than two units of OTFC for any breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> episode. </span>
</dd>
<dt>8.</dt>
<dd>Instruct patients that they MUST wait at least 4 hours before treating another episode of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with OTFC. </dd>
<dt>9.</dt>
<dd>Instruct patients NOT to share OTFC and that sharing OTFC with anyone else could result in the other individualâ€™s <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. </dd>
<dt>10.</dt>
<dd>Make patients aware that OTFC contains fentanyl which is a strong <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medication similar to hydromorphone, methadone, morphine, oxycodone, and oxymorphone. </dd>
<dt>11.</dt>
<dd>Instruct patients that the active ingredient in OTFC, fentanyl, is a drug that some people abuse. OTFC should be taken only by the patient it was prescribed for, and it should be protected from <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">theft</span> or misuse in the work or home environment. </dd>
<dt>12.</dt>
<dd>Caution patients to talk to their doctor if breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> is not alleviated or worsens after taking OTFC. </dd>
<dt>13.</dt>
<dd>Instruct patients to use OTFC exactly as prescribed by their doctor and not to take OTFC more often than prescribed. </dd>
<dt>14.</dt>
<dd>Caution patients that OTFC can affect a personâ€™s ability to perform activities that require a high level of attention (such as driving or using heavy machinery). Warn patients taking OTFC of these dangers and counsel them accordingly. </dd>
<dt>15.</dt>
<dd>Warn patients to not combine OTFC with alcohol, sleep aids, or tranquilizers except by the orders of the prescribing physician, because dangerous additive effects may occur, resulting in serious injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </dd>
<dt>16.</dt>
<dd>Inform female patients that if they become pregnant or plan to become pregnant during treatment with OTFC, they should ask their doctor about the effects that OTFC (or any medicine) may have on them and their unborn children. </dd>
<dt>17.</dt>
<dd>Physicians and dispensing pharmacists must specifically question patients or caregivers about the presence of children in the home (on a full time or visiting basis) and counsel them regarding the dangers to children from inadvertent exposure.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e4c0217f-bd00-4783-88a1-08cfc5903857"></a><a name="section-16.2"></a><p></p>
<h2>17.2 Dental Care</h2>
<p class="First">Because each OTFC unit contains approximately 2 grams of sugar, frequent consumption may increase the risk of <span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">dental decay</span>. The occurrence of <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> associated with the use of opioid medications (such as fentanyl) may add to this risk.</p>
<p>Post-marketing reports of <span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">dental decay</span> have been received in patients taking OTFC [ <span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_12b59e12-0590-43a8-a2f7-c346a69e8436">6.2</a>)</span>]. In some of these patients, <span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">dental decay</span> occurred despite reported routine oral hygiene. As <span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">dental decay</span> in cancer patients may be multi-factorial, patients using OTFC should consult their dentist to ensure appropriate oral hygiene.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f7eaa487-bc94-4d15-ba28-f91fcbe99613"></a><a name="section-16.3"></a><p></p>
<h2>17.3 Diabetic Patients</h2>
<p class="First">Advise diabetic patients that OTFC contains approximately 2 grams of sugar per unit.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d65817e7-0812-4b04-8b1f-63f8fa54bf73"></a><a name="section-16.4"></a><p></p>
<h2>17.4 OTFC Child Safety Kit</h2>
<p class="First">Provide patients and their caregivers who have children in the home or visiting with an Oral Transmucosal Fentanyl Citrate (OTFC) Child Safety Kit, which contains educational materials and safe interim storage containers to help patients store OTFC and other medicines out of the reach of children. To obtain a supply of Child Safety Kits, healthcare professionals can call PAR PHARMACEUTICAL at 1-800-391-5974.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_feae8f98-4804-4c17-ae0b-e6a86c38da38"></a><a name="section-16.5"></a><p></p>
<h2>17.5 Disposal of Used OTFC Units</h2>
<p class="First">Patients must be instructed to dispose of completely used and partially used OTFC units.</p>
<p>1) After consumption of the unit is complete and the matrix is totally dissolved, throw away the handle in a trash container that is out of the reach of children.</p>
<p>2) If any of the drug matrix remains on the handle, place the handle under hot running tap water until all of the drug matrix is dissolved, and then dispose of the handle in a place that is out of the reach of children.</p>
<p>3) Dispose of handles in the child-resistant container (as described in steps 1 and 2) at least once a day.</p>
<p><span class="Bold">If the patient does not entirely consume the unit and the remaining drug cannot be immediately dissolved under hot running water, the patient or caregiver must temporarily store the OTFC unit in the specially provided child-resistant container out of the reach of children until proper disposal is possible.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b7e38cb6-bc87-43bc-9bb2-451a47cec132"></a><a name="section-16.6"></a><p></p>
<h2>17.6 Disposal of Unopened OTFC Units When No Longer Needed</h2>
<p class="First">Patients and members of their household must be advised to dispose of any unopened units remaining from a prescription as soon as they are no longer needed.</p>
<p>To dispose of the unused OTFC units:</p>
<p>1) Remove the OTFC unit from its <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package using scissors, and hold the OTFC by its handle over the toilet bowl.</p>
<p>2) Using wire-cutting pliers cut off the drug matrix end so that it <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> into the toilet.</p>
<p>3) Dispose of the handle in a place that is out of the reach of children.</p>
<p>4) Repeat steps 1, 2, and 3 for each OTFC unit. Flush the toilet twice after 5 units have been cut and deposited into the toilet.</p>
<p>Do not flush the entire OTFC units, OTFC handles, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages, or cartons down the toilet. Dispose of the handle where children cannot reach it [ <span class="Italics">see How Supplied<span class="Bold">/</span>Storage And Handling (<a href="#i4i_section_id_c9569ac2-f8e5-492d-b4ee-67300f5e78a9">16.1</a>)</span>]<span class="Italics">.</span></p>
<p>Detailed instructions for the proper storage, administration, disposal, and important instructions for managing an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of OTFC are provided in the OTFC <span class="Italics">Medication Guide</span>. Encourage patients to read this information in its entirety and give them an opportunity to have their questions answered.</p>
<p>In the event that a caregiver requires additional assistance in disposing of excess unusable units that remain in the home after a patient has expired, instruct them to call the toll-free number for PAR PHARMACEUTICAL (1-800-828-9393) or seek assistance from their local DEA office.</p>
<p>FentoraÂ® is a registered trademark of Cephalon.</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="ID_5ee85db1-44c0-4273-8a3e-43d01d7b47b6"></a><a name="section-17"></a><p></p>
<h1>17.7 MEDICATION GUIDE </h1>
<p class="First"><span class="Bold">Oral Transmucosal Fentanyl Citrate (OTFC)</span> CII</p>
<p><span class="Bold">200 mcg, 400 mcg, 600 mcg, 800 mcg, 1200 mcg, 1600 mcg</span></p>
<p><span class="Bold">IMPORTANT:</span></p>
<p><span class="Bold">Do not use Oral Transmucosal Fentanyl Citrate (OTFC) unless you are regularly using another opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicine around-the-clock for at least one week or longer for your cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and your body is used to these medicines (this means that you are opioid tolerant). You can ask your healthcare provider if you are opioid tolerant.</span></p>
<p><span class="Bold">Keep Oral Transmucosal Fentanyl Citrate (OTFC) in a safe place away from children</span>.</p>
<p><span class="Bold">Get emergency medical help right away if:</span></p>
<p>â€¢<span class="Bold">a child takes Oral Transmucosal Fentanyl Citrate (OTFC). Oral Transmucosal Fentanyl Citrate (OTFC) can cause an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in any child who uses it</span>.â€¢<span class="Bold">an adult who has not been prescribed Oral Transmucosal Fentanyl Citrate (OTFC) uses it.</span>â€¢<span class="Bold">an adult who is not already taking opioids around-the-clock, uses Oral Transmucosal Fentanyl Citrate (OTFC).</span></p>
<p><span class="Bold">These are medical emergencies that can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. If possible, remove Oral Transmucosal Fentanyl Citrate (OTFC) from the mouth.</span></p>
<p><span class="Bold">Read the Medication Guide completely </span>before you start using OTFC and each time you get a new prescription. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or your treatment. Share this important information with members of your household and other caregivers.</p>
<p><span class="Bold">What is the most important information I should know about Oral Transmucosal Fentanyl Citrate (OTFC)?</span></p>
<p><span class="Bold">OTFCÂ can cause life-threatening breathing problems which can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>:</span></p>
<p>1.<span class="Bold">Do not use OTFC if you are not opioid tolerant.</span>2.If you stop taking your around-the-clock opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicine for your cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="Bold">you must stop</span> using OTFC. You may no longer be opioid tolerant. Talk to your healthcare provider about how to treat your <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.3.<span class="Bold">Use OTFC exactly as prescribed by your healthcare provider</span>.âˆ˜You must not use more than 1 unit of OTFC at a time and no more than 2 units of OTFC during each episode of breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.âˆ˜You must wait at least 4 hours before treating a new episode of breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. <span class="Bold">See the Medication Guide sectionâ€œHow should I use OTFC?â€? and the Patient Instructions for Use at the end of this Medication Guide about how to use OTFC the right way.</span>4.<span class="Bold">Do not switch from OTFC to other medicines that contain fentanyl without talking with your healthcare provider.</span> The amount of fentanyl in a dose of OTFC is not the same as the amount of fentanyl in other medicines that contain fentanyl. Your healthcare provider will prescribe a starting dose of OTFC that may be different than other fentanyl containing medicines you may have been taking.5.<span class="Bold">Do not</span>use OTFC for short-term <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> that you would expect to go away in a few days, such as:âˆ˜<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> after surgeryâˆ˜<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or migraineâˆ˜dental pain6.<span class="Bold">Never give OTFC to anyone else</span>, even if they have the same symptoms you have. It may harm them or even cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. OTFC is a federally controlled substance (CII) because it is a strong opioid (narcotic) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicine that can be misused by people who abuse prescription medicines or street drugs.âˆ˜<span class="Bold">Prevent <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">theft</span>, misuse or abuse. Keep OTFC in a safe place</span> to protect it from being stolen. OTFC can be a target for people who abuse opioid (narcotic) medicines or street drugs.âˆ˜<span class="Bold">Selling or giving away this medicine is against the law.</span>7.OTFC is available only through a program called the <span class="Bold">T</span>ransmucosal <span class="Bold">I</span>mmediate <span class="Bold">R</span>elease <span class="Bold">F</span>entanyl (TIRF) <span class="Bold">R</span>isk <span class="Bold">E</span>valuation and <span class="Bold">M</span>itigation <span class="Bold">S</span>trategy (REMS) Access program. To receive OTFC, you must:âˆ˜talk to your healthcare providerâˆ˜understand the benefits and risks of OTFCâˆ˜agree to all of the instructionsâˆ˜sign the Patient-Prescriber Agreement form</p>
<p><span class="Bold">What is Oral Transmucosal Fentanyl Citrate (OTFC)?</span></p>
<p>â€¢OTFC is a prescription medicine that contains the medicine fentanyl.â€¢OTFCÂ is used to manage breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in adults (16 years of age and older) with cancer who are already routinely taking other opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicines around-the-clock for cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.â€¢OTFCÂ is started only after you have been taking other opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicines and your body has become used to them (you are opioid tolerant). DO NOT USE OTFCÂ if you are not opioid tolerant.â€¢OTFC is a lozenge (attached to a handle) that you place between your cheek and lower gum and suck on to dissolve.â€¢You must stay under your healthcare providerâ€™s care while using OTFC.âˆ˜available through the TIRF REMS Access programâˆ˜given to people who are opioid tolerant</p>
<p>It is not known if OTFC is safe and effective in children under 16 years of age.</p>
<p><span class="Bold">Who should not use Oral Transmucosal Fentanyl Citrate (OTFC)?</span></p>
<p><span class="Bold">Do Not Take OTFC:</span></p>
<p>â€¢<span class="Bold">if you are not opioid tolerant. Opioid tolerant means that you are already taking other opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicines around-the-clock for at least one week or longer for your cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and your body is used to these medicines</span>.âˆ˜<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> after surgeryâˆ˜<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or migraineâˆ˜dental painâ€¢if you are allergic to any of the ingredients in OTFC. See the end of this Medication Guide for a complete list of ingredients in OTFC.</p>
<p><span class="Bold">What should I tell my healthcare provider before using Oral Transmucosal Fentanyl Citrate (OTFC)?</span></p>
<p>Before using OTFC, tell your healthcare provider if you:</p>
<p>â€¢have trouble breathing or lung problems such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, or shortness of breathâ€¢have or had a <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span> or brain problemâ€¢have liver or kidney problemsâ€¢have seizuresâ€¢have a slow heart rate or other heart problemsâ€¢have low blood pressureâ€¢have mental problems including <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span>, <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (seeing or hearing things that are not there)â€¢have a past or present drinking problem (<span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span>), or a family history of drinking problemsâ€¢have a past or present drug abuse or addiction problem, or a family history of a drug abuse problem or addiction problemâ€¢have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Each OTFC unit contains about Â½ teaspoon (2 grams) of sugarâ€¢have any other medical conditionsâ€¢are pregnant or plan to become pregnant. OTFC may cause serious harm to your unborn baby.â€¢are breastfeeding or plan to breastfeed. OTFC passes into your breast milk. It can cause serious harm to your baby. You should not use OTFC while breastfeeding.</p>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take</span>, including prescription and non-prescription medicines, vitamins, and herbal supplements. Some medicines may cause serious or life-threatening side effects when taken with OTFC. Sometimes, the doses of certain medicines and OTFC may need to be changed if used together.</p>
<p>â€¢Do not take any medicine while using OTFC until you have talked to your healthcare provider. Your healthcare provider will tell you if it is safe to take other medicines while you are using OTFC.â€¢Be very careful about taking other medicines that may make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>, such as other <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicines, anti-depressants, sleeping pills, anti-<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> medicines, antihistamines, or tranquilizers.</p>
<p>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I use Oral Transmucosal Fentanyl Citrate (OTFC)?</span></p>
<p><span class="Bold">Before you can begin to use OTFC:</span></p>
<p>â€¢Your healthcare provider will explain the TIRF REMS Access program to you.â€¢You will sign the TIRF REMS Access program Patient-Prescriber Agreement form.â€¢OTFC is only available at pharmacies that are part of the TIRF REMS Access program. Your healthcare provider will let you know the pharmacy closest to your home where you can have your OTFC prescription filled.</p>
<p><span class="Bold">Using OTFC:</span></p>
<p>â€¢<span class="Bold">Use OTFC exactly as prescribed. Do not use OTFC more often than prescribed.</span>â€¢Your healthcare provider will change the dose until you and your healthcare provider find the right dose for you.â€¢<span class="Bold">See the detailed Patient Instructions for Use at the end of this Medication Guide for information about how to use OTFC the right way.</span>â€¢Finish the OTFC unit completely in 15 minutes to get the most relief. If you finish OTFC too quickly, you will swallow more of the medicine and get less relief.â€¢<span class="Bold">Do not bite or chew OTFC. You will get less relief for your breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</span>â€¢You may drink some water before using OTFC but you should not drink or eat anything while using OTFC.âˆ˜Use <span class="Bold">1</span> unit for an episode of breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Finish the unit over 15 minutes.âˆ˜If your breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> is not relieved 15 minutes after you finished the OTFC unit, use <span class="Bold">only 1</span> more unit of OTFC at this time.âˆ˜If your breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> does not get better after the second unit of OTFC, call your healthcare provider for instructions. <span class="Bold">Do not use another unit of OTFC at this time</span>.â€¢Wait at least <span class="Bold">4</span>hours before treating a new episode of breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with OTFC.â€¢It is important for you to keep taking your around-the-clock opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicine while using OTFC.â€¢Talk to your healthcare provider if your dose of OTFC does not relieve your breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Your healthcare provider will decide if your dose of OTFC needs to be changed.â€¢Talk to your healthcare provider if you have more than 4 episodes of breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> per day. The dose of your around-the-clock opioid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicine may need to be adjusted.â€¢If you begin to feel dizzy, sick to your stomach, or very <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> before OTFC is completely dissolved, remove OTFC from your mouth.â€¢If you use too much OTFC or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, you or your caregiver should call for emergency medical help or have someone take you to the nearest hospital emergency room right away.</p>
<p><span class="Bold">What should I avoid while using Oral Transmucosal Fentanyl Citrate (OTFC)?</span></p>
<p>â€¢<span class="Bold">Do not drive, operate heavy machinery, or do other dangerous activities</span> until you know how OTFC affects you. OTFC can make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>. Ask your healthcare provider when it is okay to do these activities.â€¢<span class="Bold">Do not drink alcohol while using OTFC.</span>It can increase your chance of getting dangerous side effects.</p>
<p><span class="Bold">What are the possible side effects of Oral Transmucosal Fentanyl Citrate (OTFC)?</span></p>
<p><span class="Bold">OTFC can cause serious side effects, including:</span></p>
<p>1.<span class="Bold">Breathing problems that can become life-theatening. See â€œWhat is the most important information I should know aboutOTFC?â€?Call your healthcare provider or get emergency medical help right away if you:</span>âˆ˜have trouble breathingâˆ˜have <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> with slowed breathingâˆ˜have slow <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span> (little chest movement with breathing)âˆ˜feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, very dizzy, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span>, or have other unusual symptoms.These symptoms can be a sign that you have used too much OTFC or the dose is too high for you. <span class="Bold">These symptoms may lead to serious problems or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> if not treated right away. If you have any of these symptoms, do not use any more OTFC until you have talked to your healthcare provider.</span>2.<span class="Bold">Decreased blood pressure.</span> This can make you feel dizzy or lightheaded if you get up too fast from sitting or lying down.3.<span class="Bold">Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Do not stop taking OTFC or any other opioid, without talking to your healthcare provider.</span> You could become sick with uncomfortable withdrawal symptoms because your body has become used to these medicines. Physical dependency is not the same as <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug addiction</span>.4.<span class="Bold">A chance of abuse or addiction.</span>This chance is higher if you are or have ever been addicted to or abused other medicines, street drugs, or alcohol, or if you have a history of mental health problems. The most common side effects of OTFC are:âˆ˜nauseaâˆ˜vomitingâˆ˜dizzinessâˆ˜sleepinessâˆ˜weaknessâˆ˜headacheâˆ˜anxietyâˆ˜confusionâˆ˜depressionâˆ˜rashâˆ˜trouble sleeping</p>
<p><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> (not often enough or hard bowel movements) is a very common side effect of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicines (opioids) including OTFC and is unlikely to go away without treatment. Talk to your healthcare provider about dietary changes, and the use of laxatives (medicines to treat <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>) and stool softeners to prevent or treat <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> while taking OTFC.</p>
<p>OTFC contains sugar. Cavities and <span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">tooth decay</span> can happen in people taking OTFC. When taking OTFC, you should talk to your dentist about proper care of your teeth.</p>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of OTFC. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store Oral Transmucosal Fentanyl Citrate (OTFC)?</span></p>
<p>â€¢<span class="Bold">Always keep OTFC in a safe place away from children and from anyone for whom it has not been prescribed.</span>Protect OTFC from <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">theft</span>.âˆ˜You can use the OTFC Child Safety Kit to help you store OTFC and your other medicines out of the reach of children. It is very important that you use the items in the OTFC Child Safety Kit to help protect the children in your home or visiting your home.âˆ˜If you were not offered a Child Safety Kit when you received your medicine, call PAR PHARMACEUTICAL at 1-800-391-5974 to request one.</p>
<p>The OTFC Child Safety Kit contains important information on the safe storage and handling of OTFC.</p>
<p>The Child Safety Kit includes:</p>
<p>â€¢<span class="Bold">A child-resistant lock that</span> you use to secure the storage space where you keep OTFC (See <span class="Bold">Figure 1</span>).</p>
<div class="Figure"><img alt="This is Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-06.jpg"></div>
<p></p>
<p class="MultiMediaCaption">Figure 1</p>
<p class="MultiMediaCaption">Figure 1</p>
<p>â€¢<span class="Bold">A portable locking pouch</span>for you to keep a small supply of OTFC nearby. The rest of your OTFC must be kept in a locked storage space.âˆ˜Keep this pouch secured with its lock and keep it out of the reach and sight of children (See <span class="Bold">Figure 2</span>).</p>
<div class="Figure"><img alt="This is fig 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-07.jpg"></div>
<p></p>
<p class="MultiMediaCaption">Figure 2</p>
<p class="MultiMediaCaption">Figure 2</p>
<p>â€¢<span class="Bold">A child-resistant temporary storage bottle</span> (See <span class="Bold">Figure 3</span>).</p>
<div class="Figure"><img alt="this is fig 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-08.jpg"></div>
<p></p>
<p class="MultiMediaCaption">Figure 3</p>
<p class="MultiMediaCaption">Figure 3</p>
<p>â€¢Store OTFC at room temperature, 25Â°C to 25Â°C (68Â°F to 77Â°F) [See USP Controlled Room Temperature] until ready to use.â€¢Do not freeze OTFC.â€¢<span class="Bold">Keep OTFC in the original sealed child-resistant <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package. Do not open the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package until you are ready to use OTFC.</span>â€¢Keep OTFC dry.</p>
<p><span class="Bold">How should I dispose of Oral Transmucosal Fentanyl Citrate (OTFC)Â units when they are no longer needed?</span></p>
<p><span class="Bold">Disposing of OTFC units after use:</span></p>
<p>Partially used OTFCÂ units may contain enough medicine to be harmful or fatal to a child or other adults who have not been prescribed OTFC. <span class="Bold">You must properly dispose of the OTFC handle right away after use even if there is little or no medicine left on it. </span></p>
<p>After you have finished the OTFC unit and the medicine is totally gone, throw the handle away in a place that is out of the reach of children.</p>
<p>If <span class="Bold">any</span> medicine remains on the used OTFC unit after you have finished:</p>
<p>â€¢Place the used OTFC unit under hot running water until the medicine is gone, and then throw the handle away out of the reach of children and pets (See Figure 4).</p>
<div class="Figure"><img alt="this is the sink" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-09.jpg"></div>
<p></p>
<p class="MultiMediaCaption">Figure 4</p>
<p class="MultiMediaCaption">Figure 4</p>
<p><span class="Bold"><span class="Underline">Temporary Storage ofUsed OTFC Units</span>:</span></p>
<p>â€¢If you did not finish the entire OTFC unit and you cannot dissolve the medicine under hot running water right away, put the OTFCÂ in the temporary storage bottle that you received in the OTFCÂ Child Safety Kit. Push the used OTFC unit into the opening on the top until it <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> completely into the bottle. <span class="Bold">Never leave unused or partially used OTFC units where children or pets can get to them</span> (See <span class="Bold">Figure 5</span>)<span class="Bold">.</span></p>
<div class="Figure"><img alt="this is fig 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-10.jpg"></div>
<p></p>
<p class="MultiMediaCaption">Figure 5</p>
<p class="MultiMediaCaption">Figure 5</p>
<p><span class="Underline"><span class="Bold">Disposing of Used OTFC Units from the Temporary Storage Bottle</span>:</span></p>
<p><span class="Bold">You must</span> dispose of all used OTFC units in the temporary storage bottle <span class="Bold">at least one time each day</span>, as follows:</p>
<p>1.To open the temporary storage bottle, push down on the cap until you are able to twist the cap to the left to remove it (See <span class="Bold">Figure 6</span>).</p>
<div class="Figure"><img alt="this is fig 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-11.jpg"></div>
<p></p>
<p class="MultiMediaCaption">Figure 6</p>
<p class="MultiMediaCaption">Figure 6</p>
<p>2.Remove one OTFC unit from the temporary storage bottle. Hold the OTFC by its handle over the toilet bowl.3.Using wire-cutting pliers, cut the medicine end off so that it <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> into the toilet.4.Throw the handle away in a place that is out of the reach of children.5.Repeat these 3 steps for each OTFC handle that is in the storage bottle. There should not be more than 4 handles in the temporary storage bottle for 1 day.6.Flush the toilet twice.</p>
<p>Do not flush entire unused OTFC units, OTFC handles, or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages down the toilet.</p>
<p><span class="Bold">Disposing of unopened OTFC units:</span> Dispose of any unopened OTFC units remaining from a prescription as soon as they are no longer needed, as follows:</p>
<p>1.Remove all OTFC from the locked storage space (See <span class="Bold">Figure 7</span>).</p>
<div class="Figure"><img alt="this is figure 7" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-12.jpg"></div>
<p></p>
<p class="MultiMediaCaption">Figure 7</p>
<p class="MultiMediaCaption">Figure 7</p>
<p>2.Remove one OTFC unit from its <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package by using scissors to cut off the marked end and then peel back the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> backing (See <span class="Bold">Figures 8A</span> and <span class="Bold">8B</span>).</p>
<div class="Figure"><img alt="This is fig 8AB" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-13.jpg"></div>
<p></p>
<p class="MultiMediaCaption">Figures 8A and 8B</p>
<p class="MultiMediaCaption">Figures 8A and 8B</p>
<p>3.Hold OTFC by its handle over the toilet bowl. Use wire-cutting pliers to cut the medicine end off so that it <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> into the toilet (See <span class="Bold">Figures 9A</span> and <span class="Bold">9B</span>).</p>
<div class="Figure"><img alt="This is 9AB" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-14.jpg"></div>
<p></p>
<p class="MultiMediaCaption">Figures 9A and 9B</p>
<p class="MultiMediaCaption">Figures 9A and 9B</p>
<p>4.Throw the handle away in a place that is out of the reach of children (See <span class="Bold">Figure 10</span>).</p>
<div class="Figure"><img alt="this is fig 10" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-15.jpg"></div>
<p></p>
<p class="MultiMediaCaption">Figure 10</p>
<p class="MultiMediaCaption">Figure 10</p>
<p>5.Repeat steps 1 through 4 for each OTFC unit.6.Flush the toilet twice after the medicine ends from 5 OTFC units have been cut off (See <span class="Bold">Figure 11</span>). Do not flush more than 5 OTFC units at a time.</p>
<div class="Figure"><img alt="this is fig 11" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-16.jpg"></div>
<p></p>
<p class="MultiMediaCaption">Figure 11</p>
<p class="MultiMediaCaption">Figure 11</p>
<p>â€¢Do not flush entire unused OTFC units, OTFC handles, or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages down the toilet.</p>
<p>If you need help with disposal of OTFC, call PAR PHARMACEUTICAL, at 1-800-828-9393, or call your local Drug Enforcement Agency (DEA) office.</p>
<p><span class="Bold">General information about Oral Transmucosal Fentanyl Citrate (OTFC)</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. <span class="Bold">Use OTFC only for the purpose for which it was prescribed. Do not give OTFC to other people, even if they have the same symptoms you have.</span> OTFC can harm other people and even cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Sharing OTFC is against the law.</p>
<p>This Medication Guide summarizes the most important information about OTFC. If you would like more information, talk with your healthcare provider or pharmacist. You can ask your pharmacist or healthcare provider for information about OTFC that is written for healthcare professionals.</p>
<p>For more information about the TIRF REMS Access program, go to www. TIRFREMSaccess.com or call 1-866-822-1483.</p>
<p><span class="Bold">What are the ingredients of Oral Transmucosal Fentanyl Citrate (OTFC)?</span></p>
<p><span class="Bold">Active Ingredient: </span>fentanyl citrate</p>
<p><span class="Bold">Inactive Ingredients: </span>Anhydrous citric acid, artificial raspberry flavor, confectionerâ€™s sugar, dextrates, dibasic sodium phosphate, FD&amp;C blue no. 1, magnesium stearate, pregelatinized starch, propylene glycol and purified shellac.</p>
<p><span class="Bold">Patient Instructions for Use</span></p>
<p>Before you use OTFC, it is important that you read the Medication Guide and these Patient Instructions for Use. Be sure that you read, understand, and follow these Patient Instructions for Use so that you use OTFC the right way. Ask your healthcare provider or pharmacist if you have any questions about the right way to use OTFC.</p>
<p><span class="Bold">When you get an episode of breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, use the dose of OTFC prescribed by your healthcare provider as follows:</span></p>
<p>â€¢You may drink some water before using OTFC but you should not drink or eat anything while using OTFC.â€¢Each unit of OTFC is sealed in its own <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package (See <span class="Bold">Figure 12</span>). <span class="Bold">Do not open the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package until you are ready to use OTFC.</span></p>
<div class="Figure"><img alt="this is fig 12" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-17.jpg"></div>
<p></p>
<p class="MultiMediaCaption">Figure 12</p>
<p class="MultiMediaCaption">Figure 12</p>
<p>â€¢When you are ready to use OTFC, cut open the package using scissors. Peel back the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> backing, and remove the OTFC unit (See <span class="Bold">Figures 13A</span> and <span class="Bold">13B</span>). The end of the unit printed with â€œOTFCâ€? and the strength number of the unit (â€œ200â€?, â€œ400â€?, â€œ600â€?, â€œ800â€?, â€œ1200â€?, or â€œ1600â€?) is the medicine end that is to be placed in your mouth. Hold the OTFC unit by the handle (See <span class="Bold">Figure 14</span>).</p>
<div class="Figure"><img alt="this is fig 13AB" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-18.jpg"></div>
<p></p>
<p class="MultiMediaCaption">Figures 13A and 13B</p>
<p class="MultiMediaCaption">Figures 13A and 13B</p>
<div class="Figure"><img alt="this is fig 14" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-19.jpg"></div>
<p></p>
<p class="MultiMediaCaption">Figure 14</p>
<p class="MultiMediaCaption">Figure 14</p>
<p>1.Place the medicine end of the OTFC unit in your mouth between your cheeks and gums and actively suck on the medicine.2.Move the medicine end of the OTFC unit around in your mouth, especially along the inside of your cheeks (See <span class="Bold">Figure 15</span>).</p>
<div class="Figure"><img alt="this is fig 15" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-20.jpg"></div>
<p></p>
<p class="MultiMediaCaption">Figure 15</p>
<p class="MultiMediaCaption">Figure 15</p>
<p>3.Twirl the handle often.4.Finish the OTFC unit completely over 15 minutes to get the most relief. If you finish OTFC too quickly, you will swallow more of the medicine and get less relief.5.<span class="Bold">Do not bite or chew OTFC. You will get less relief for your breakthrough cancer <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</span>â€¢If you cannot finish all of the medicine on the OTFC unit and cannot dissolve the medicine under hot tap water right away, immediately put the OTFC unit in the temporary storage bottle for safe keeping (See <span class="Bold">Figure 16</span>).âˆ˜Push the OTFC unit into the opening on the top until it <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> completely into the bottle. You must properly dispose of the OTFC unit as soon as you can.</p>
<div class="Figure"><img alt="this is fig 16" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=a5cd9a90-2ac3-4b4a-b35f-328721e44374-21.jpg"></div>
<p class="MultiMediaCaption">Figure 16</p>
<p class="MultiMediaCaption">Figure 16</p>
<p><span class="Bold">See â€œHow should I dispose of Oral Transmucosal Fentanyl Citrate (OTFC) units when they are no longer needed?â€?</span> for proper disposal of OTFC.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured By:</p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA</span></p>
<p>Sellersville, PA 18960</p>
<p>Manufactured For:</p>
<p>Par Pharmaceutical</p>
<p>Spring Valley, NY 10977</p>
<p>Rev. G 1/2012</p>
<p>[Enter Medication Guide here]</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="L64bc5736-1ab6-40c4-b99c-4557d0e9f680"></a><a name="section-18"></a><p></p>
<h1>Image of Label</h1>
<p class="First"><img alt="Image of Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f&amp;name=Fentanyl800mcgLozengeTeva.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FENTANYL CITRATEÂ 		
					</strong><br><span class="contentTableReg">fentanyl citrate lozenge</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:35356-999(NDC:49884-462)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL, TRANSMUCOSAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FENTANYL CITRATE</strong> (FENTANYL) </td>
<td class="formItem">FENTANYL</td>
<td class="formItem">800Â ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>RASPBERRY</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DEXTRATES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (cylindrical) </td>
<td class="formLabel">Size</td>
<td class="formItem">20mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">RASPBERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Fentanyl;800;mcg;4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:35356-999-30</td>
<td class="formItem">30  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077312</td>
<td class="formItem">10/17/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Lake Erie Medical DBA Quality Care Products LLC
							(831276758)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Lake Erie Medical DBA Quality Care Products LLC</td>
<td class="formItem"></td>
<td class="formItem">831276758</td>
<td class="formItem">relabel(35356-999)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>34beb750-b5cd-4ac4-914c-81d6906fcb3d</div>
<div>Set id: 8c3a8b2e-3ec2-4fad-bb9f-838822d97e6f</div>
<div>Version: 1</div>
<div>Effective Time: 20130820</div>
</div>
</div>Â <div class="DistributorName">Lake Erie Medical DBA Quality Care Products LLC</div></p>
</body></html>
